

Preface

Today, as it has been for centuries, tuberculosis remains the leading cause of death in the world from infectious disease. Approximately a third of the world's population has been infected with *Mycobacterium tuberculosis* and is at risk for developing disease. Globally, tuberculosis accounts for almost 3 million deaths annually and one-fifth of all deaths of adults in developing countries. Tuberculosis is a reemergent problem in many industrialized countries. In the modern world of global interdependency, rapid transportation, expanding trade, and changing social and cultural patterns, tuberculosis in any country is a threat to people in every country. In the context of infectious diseases, there is no place in the world from which we are remote and no one from whom we are disconnected.

Current knowledge of evolutionary biology and genetics makes clear that what is at stake in the battle against infectious diseases is the survival not only of human and animal hosts but of the pathogens themselves, a confrontation that cannot be taken lightly. Human interventions serve as selections for genetic mutations, adaptations, and migrations that enable pathogens to survive. While societies traditionally deal with epidemics and outbreaks of infectious diseases in an episodic or discontinuous fashion, the evolutionary process of the pathogens is a continuous one. That elementary truth demands vigilance rather than complacency in applying the tools we have and a continuing scientific effort both to anticipate new threats from infectious pathogens and to develop new tools with which to protect the public health. In the case of tuberculosis, the demise of the

disease in the industrialized world has been taken for granted and its persistence in developing countries largely ignored. Support for research dwindled, and the expertise of a generation of scientists and clinicians knowledgeable about tuberculosis was lost.

The current global reemergence of tuberculosis can be attributed to several factors. The compromise of immune mechanisms in human immunodeficiency virus (HIV)-infected individuals that leads either to reactivation of old tuberculous infections or to increased susceptibility to new infection is a major contributor to the increasing incidence of tuberculosis. Other factors are social dislocations, poverty, overcrowding, and a failure to invest in public health infrastructures. Particularly ominous is the emergence of multidrug-resistant tubercle bacilli. In the preantibiotic era, the case fatality rate of untreated tuberculosis was about 50%. With appropriate treatment, cure rates greater than 85% can now be achieved in both HIV-positive and immunocompetent individuals with conventional tuberculosis, even in developing countries. However, the case fatality rates of multidrug-resistant tuberculosis in the United States are about 40% for immunocompetent individuals and over 80% for HIV-infected individuals. Thus, tuberculosis has emerged as a major and devastating global threat to health, and many of the tools currently available for rapid diagnosis, prevention, and treatment are woefully lacking.

The aim of this book is to provide in one volume an overview of the current state of knowledge about tuberculosis and a critical appraisal of the exciting new molecular, immunological, and epidemiological ap-

proaches to understanding and controlling tuberculosis. The emphasis is on research. The authors hope to make existing knowledge and new avenues of research accessible to a new generation of researchers and clinicians. We hope to encourage scientists, clinicians, and students in many disciplines to undertake research on tuberculosis and want to facilitate the rapid generation of new knowledge, insights, and interventions.

Distinguished scientists knowledgeable in major areas of tuberculosis research and control have contributed critical reviews of current understanding and their thoughts on new approaches to each area. For most chapters in this book, I asked world experts to write collaboratively in order to provide balance, multiple perspectives on key issues, and critical delineation of the areas of consensus and contention. The authors were asked to be provocative rather than comprehensive. Our hope is that most chapters will be read with interest by anyone concerned with tuberculosis. Our intention is for the book to serve both as a challenge to scientists knowledgeable about aspects of tuberculosis and as a useful introduction to those with expertise in other disciplines who may wish to apply their knowledge and skills to the problem of tuberculosis. We hope, too, that the book will make accessible to scientists and students in developing countries, where the needs are greatest, the excitement of the new approaches to pathogenesis, resistance, and control.

This book is intended to honor rather

than replace some of the classic sources of knowledge about tuberculosis. The classic studies of A. R. Rich (*The Pathogenesis of Tuberculosis*, 2nd ed., 1,028 p., Charles C Thomas, Publisher, 1951) and G. Canetti (*The Tubercle Bacillus in the Pulmonary Lesion of Man*, 226 p., Springer, 1955) on the pathogenesis of the human disease, of L. Barksdale and K.-S. Kim on the characteristics of the genus *Mycobacterium* (*Bacteriological Reviews*, 41:217-372, 1977), of M. B. Lurie (*Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms*, Harvard University Press, Cambridge, Mass., 1964) on experimental tuberculosis, and of K. Styblo (*Epidemiology of Tuberculosis*, Royal Netherlands Tuberculosis Association Selected Papers, vol. 24, The Hague, 1991) on epidemiology remain important reading for any student of the disease. The comprehensive texts edited by C. Ratledge and J. Stanford (*The Biology of the Mycobacteria*, 2 vol., Academic Press, 1981) and G. B. Kubica and L. G. Wayne (*The Mycobacteria: a Sourcebook*, 2 vol., Marcel Dekker, 1984) remain a repository of much valuable information. Yet the revolution in molecular biology, genetics, and immunology and the advances in understanding epidemiology and control of the disease in both developing and industrialized countries now offer far greater opportunities than were previously available for understanding and developing improved interventions in the disease. We hope this book will make a useful contribution to filling that gap in time and knowledge.

Chapter 1

Global Burden of Tuberculosis

Dixie E. Snider, Jr., Mario Raviglione, and Arata Kochi

INTRODUCTION

The purpose of this chapter is to review the current epidemiology of tuberculosis (TB) in the world. From a global perspective, the magnitude of the TB problem is enormous. Furthermore, unless aggressive intervention is undertaken soon, the worldwide situation concerning TB will deteriorate rapidly; during this decade, nearly 90 million new cases will occur and 30 million people will die from TB. The disease is now the world's foremost cause of death from a single infectious agent.

Although in this chapter we concentrate on the number of new cases of and deaths from this disease, we recognize that these data do not fully describe the effect of the disease on the population. For example, we have not discussed the economic impact of the disease: direct and indirect costs of treatment of cases and suspected cases, costs of contact investigations, costs of TB screening and preventive therapy programs (where these are used), costs of hospital and institutional infection control programs, and costs to patients in lost income.

An increasing number of cases due to organisms multiply resistant to anti-TB drugs could escalate these costs dramatically.

Other factors we do not discuss in this chapter are the frequency of early and late complications and the impact of these complications on morbidity, mortality, and costs. There are few data on the frequency with which complications occur.

We also do not discuss the social impact of TB on the population: for example, loss of employment, decreased likelihood of marriage (especially for women), and creation of orphans and one-parent households. Again, few or no current data in the literature address these issues.

Ideally, we would like to present the exact numbers of new cases of TB and deaths from TB that occur each year. Unfortunately, disease surveillance in many countries is too incomplete to provide this information (Styblo and Rouillon, 1981). Because of this limitation, the burden of TB must be estimated indirectly by using several epidemiological parameters, including the average annual risk of TB infection, the reported incidence of smear-positive pulmonary TB, the estimated coverage of the population by health care services, the estimated proportion of all cases of TB that are smear-positive, and the estimated case-fatality rates for smear-positive and other forms of TB.

Dixie E. Snider, Jr. • Office of the Director, Centers for Disease Control and Prevention, Atlanta, Georgia 30333. *Mario Raviglione and Arata Kochi* • Tuberculosis Programme, World Health Organization, CH-1211, Geneva 27, Switzerland.

Tuberculosis Infection

The ability of the tuberculin skin test to detect the presence of *Mycobacterium tuberculosis* infection can be used to measure the prevalence of infection. A method for converting the prevalence of infection into the annual risk of infection has been developed (Styblo et al., 1969; Sutherland, 1976). The annual risk of infection is the probability that any individual will be infected with *M. tuberculosis* in 1 year. If several tuberculin surveys of the same population have been done at different times (using similar techniques and testing a representative sample of non-BCG-vaccinated subjects of the same age), the trend in the annual risk of infection can be estimated. In the absence of good surveillance systems to detect and report incident cases, calculating the annual risk of infection is a valuable technique for estimating the magnitude of the TB problem. Although there are limitations to this approach, Styblo has shown that a 1% annual risk of infection corresponds, on average, to an incidence of 50 smear-positive cases per 100,000 population (Murray et al., 1990).

Cauthen and Ten Dam (1988) have used the results of tuberculin skin test surveys done in developing countries since the 1950s to estimate the annual risks of infection in different regions of the developing world (Table 1). The annual risk of tuberculous infection is probably highest in sub-Saharan Africa, followed closely by risk in Southeast Asia.

Kochi (1991) has estimated that about one-third of the world's population, or about 1.7 billion people, is infected with *M. tuberculosis*. The great majority of the world's population, and thus the majority of infected persons, reside in developing countries. In industrialized countries, 80% of infected individuals are aged 50 years or more, while in developing countries, 75% of infected persons are less than 50 years old (Kochi, 1991).

Table 1. Estimated annual risk of TB and trends in developing countries, 1985 to 1990^a

Area(s)	Estimated annual (%):	
	Risk of infection	Decrease in risk
Sub-Saharan Africa	1.5-2.5	1-2
North Africa and western Asia	0.5-1.5	5-6
Southeast Asia	1.0-2.0	1-3
South America	0.5-1.5	2-5
Central America and Caribbean	0.5-1.5	1-3

^a Based on data in Cauthen and Ten Dam (1988).

Annual Incidence of Disease and Death

Table 2 shows the distribution of the present burden of cases and deaths. Over 8 million cases of TB occurred in 1992. Of these cases, 3.3 million were in the World Health Organization's (WHO's) Southeast Asian region, 1.9 million were in the western Pacific region, 1.2 million were in sub-Saharan Africa, and 1.6 million, including 199,000 cases in industrialized countries, were in the remainder of the world. TB has a devastating effect in the developing world, where 95% of cases occur. Eighty percent of these cases occur in persons who are in their productive years (ages 15 to 59). According to a 1989 WHO report, 1.3 million cases and 450,000 deaths from TB in developing countries occur in children under the age of 15 years (World Health Organization, 1989).

In the prechemotherapy era, mortality from TB was about 50 to 60% (Murray et al., 1990). Today, death rates in developing countries are not as high because a significant proportion of cases are detected and treated.

Nevertheless, an estimated 2.7 million persons died from TB in 1992: 1.1 million in the Southeast Asian region, 672,000 in the western Pacific region, 468,000 in the African region, and 426,000 in the remainder of the world (Table 2). TB causes over 25% of

TB and trends in
to 1990^a

ated annual (%):

Decrease in risk
1-2
5-6
1-3
2-5
1-3

(1988).

and Death

tion of the
eaths. Over 8
in 1992. Of
the World
Southeast
in the west-
were in sub-
including
countries,
d. TB has
developing
car. Eighty
persons who
s 15 to 59).
1.3 mil-
TB in
aren un-
Health

mortality
Murray et
developing
signifi-
ed and

million
in
in the
Afri-
der of

Table 2. Estimated global TB incidence and mortality in 1992

Area	Incidence		Mortality	
	No. of cases	Rate ^a	No. of deaths	Rate ^a
Southeast Asia	3,263,000	240	1,142,000	84
Western Pacific ^b	1,921,000	136	672,000	48
Africa	1,182,000	214	468,000	85
Eastern Mediterranean	683,000	166	266,000	65
Americas ^c	584,000	128	117,000	26
Eastern Europe	197,000	47	29,000	7
Industrialized countries ^d	199,000	22	14,000	2
All regions	8,029,000	146	2,708,000	49

^a Per 100,000 population.

^b All countries of the region except Australia, Japan, and New Zealand.

^c All countries of the region except Canada and the United States.

^d Western Europe plus Australia, Canada, Japan, New Zealand, and the United States.

avoidable adult deaths in the developing world (Murray et al., 1990).

Impact of the HIV-AIDS Epidemic

The pandemic of human immunodeficiency virus (HIV) infection and the evidence of an association between tuberculosis and HIV infection has caused marked increases in the incidence of TB in some countries. Because of its ability to destroy the immune system, HIV has emerged as the most significant risk factor for progression of dormant TB infection to clinical disease (Selwyn et al., 1989).

The Global Programme on AIDS of the WHO estimated that in 1992 at least 13 million adults and 1 million children had been infected with HIV worldwide (World Health Organization, 1993). Nearly 85% of HIV infections have occurred in developing countries, and the vast majority have occurred in the age group 15 to 49 years.

It is estimated that about 1,700 million people are infected with *M. tuberculosis* (Kochi, 1991). The impact of HIV infection on the TB situation is greatest in those populations where the prevalence of TB infection in young adults (who are at greatest risk of HIV infection) is high. By using estimates of the prevalence of TB infection in various regions, it has been estimated that since the beginning of the HIV pan-

demic until mid-1993, more than 5 million persons worldwide have had dual HIV and TB infection. A great majority (3.8 million) of these patients lived in sub-Saharan Africa (Fig. 1). HIV seroprevalence rates of more than 40% are common among patients with TB in many African countries. The annual risk of progression to active TB among individuals infected with both HIV and TB is 5 to 10% (Narain et al., 1992).

The result of this increased risk is evident from the reported numbers of TB cases in several countries. After years of declining incidence of the disease, the number of reported cases of TB increased dramatically during the 1980s in many countries in sub-Saharan Africa. Within a 7-year period from 1985 to 1991, the annual number of cases in Zambia nearly tripled, that in Malawi more than doubled, and those in Tanzania and Burundi increased by about 70 and 40%, respectively. The numbers of deaths from TB have also increased in these countries (Narain et al., 1992).

The situation in some countries in Southeast Asia and the western Pacific is now similar to that in Africa several years ago. Since almost two-thirds of the world's TB-infected population is in Asia, entry of HIV into Asian communities may result in large increases in HIV-associated TB in the coming years. In Bombay, HIV seroprevalence




Figure 1. Estimated global distribution of adults who have been infected with HIV and TB, as of mid-1993. Source of data is WHO Tuberculosis Programme.

among TB patients increased from 2% in 1988 to 10 to 15% in 1991 and 1992. In northern Thailand, HIV seroprevalence in TB patients increased from 5% in late 1989 to 15% in 1992, and there is evidence that the incidence of TB is increasing (World Health Organization, unpublished data).

In many developing countries, TB has emerged as the most common opportunistic disease associated with HIV infection. Twenty to forty-four percent of AIDS patients in Africa, 18% of patients in Haiti, and up to 25% of patients in some Latin American countries, namely Brazil, Mexico, and Argentina, had clinical TB during the course of HIV infection (Narain et al., 1992).

It is still unclear how the increasing numbers of HIV-positive patients with TB will affect the transmission of TB in the community. It is possible that the increase in the number of TB cases will increase TB trans-

mission to both HIV-positive and HIV-negative populations. Nevertheless, preliminary data from the second round of the National Tuberculin Survey in Tanzania, where the TB control program has achieved an 80% cure rate of patients with newly diagnosed smear-positive cases during the last 5 years and a 65% case detection rate, suggest that the prevalence of infection in school children did not change appreciably from 1983-1985 to 1989-1991, despite the increase in the number of detected new smear-positive cases (Narain et al., 1992). Thus, a good control program may be able to reduce to some extent the increased chance of transmission.

HIV-infected patients with TB also have a higher incidence of noninfectious extrapulmonary forms of disease and higher mortality rates and thus may have a lesser impact on transmission than non-HIV-infected TB patients.

TUBERCULOSIS IN INDUSTRIALIZED COUNTRIES

United States

From 1953, when national surveillance began, through 1984, the United States experienced a significant decline in TB cases: from 84,304 cases in 1953 to only 22,225 cases in 1984. The average annual decline in cases was about 5.3% per year. From 1985 to 1992, however, the number of reported cases has increased by about 20%. Using the trend for 1980 to 1984 to calculate the number of expected cases, the Centers for Disease Control and Prevention (CDC) estimates that from 1985 through 1992, about 51,000 excess cases have accumulated (Fig. 2). Case rates in urban areas have increased more rapidly than those in rural areas.

Of the 26,673 TB cases reported in 1992, 71% occurred in racial and ethnic minorities. From 1985 to 1992, TB case numbers declined about 10% among non-Hispanic whites and 23% among Native Americans. However, case numbers increased 27% among blacks, 46% among Asians and Pacific Islanders, and 75% among Hispanics.

From 1985 through 1992, all age groups, except that of patients 65 years of age and older, experienced an increase in number of cases. The largest numerical and percentage increases (+3,686; +55%) were among persons 25 to 44 years of age. However, there was a 36% increase in case numbers among 0- to 4-year-old patients and a 34% increase among children 5 to 14 years old.

Of all patients with TB reported to the CDC in 1992, 27% were born in another country. The numbers and percentages of foreign-born patients increased from 4,925 and 22% in 1986 to 7,270 and 27% in 1992.

In addition to the effect of immigration on the change in the TB morbidity trend, there is evidence that the HIV epidemic is at least in part contributing to this change. The




Figure 2. Numbers of expected and observed cases of TB in the United States from 1980 through 1992. Table is from the CDC (Centers for Disease Control and Prevention, 1993).

largest increases in reported TB case numbers have occurred in geographic areas and age groups heavily impacted by the HIV epidemic. TB prevalence among AIDS patients is high. Matching of TB and AIDS registries through 1990 revealed that 4.9% of reported AIDS cases were also in the TB registry (CDC, unpublished data). CDC HIV seroprevalence surveys in TB clinics have shown a high prevalence of HIV infection among TB patients. Pooled seroprevalence data from 13 cities that tested at least 50 serum samples per year for 1989, 1990, and 1991 showed seroprevalence rates of 13.1% in 1989, 17.8% in 1990, and 21.4% in 1991. Trend analysis from 1989 through 1991 also showed significant upward trends in HIV seroprevalence among black, Hispanic, and white males with TB or suspected TB. Among females, the upward trend was significant only for blacks (Onorato et al., 1993).

The United States has also experienced an increasing number of outbreaks of TB. Outbreaks have occurred in a variety of settings, including hospitals, correctional facilities, shelters for the homeless, residential care facilities for patients with AIDS, nursing homes, and even crack houses.

The most serious problem has been the outbreaks of multidrug-resistant TB (MDR-



as of mid-1993.

and HIV-
theless, pre-
round of the
in Tanzania,
has achieved
with newly
s during the
fection rate,
infection in
appreciably
despite the
ected new
t al., 1992).
may be able
e increased

B also have
tious extra-
and higher
ave a lesser
ion-HIV-in-

TB), i.e., outbreaks due to organisms resistant to isoniazid and rifampin (and often other drugs as well). From 1990 through 1992, the CDC investigated outbreaks of MDR-TB in eight hospitals and a state correctional system. As of November 1992, 297 cases of MDR-TB had been identified in these outbreaks. Most but not all of the cases occurred in persons infected with HIV. Mortality was high (about 70%), and the median interval from TB diagnosis to death was short (4 to 16 weeks). The outbreak investigations demonstrated transmission of infection to health care workers. At least 17 health care and correctional workers have developed active TB with multidrug-resistant organisms (CDC, unpublished data).

Factors contributing to nosocomial outbreaks include the convergence of highly susceptible, immunocompromised patients and TB patients; the delayed recognition of TB (because of unconsidered diagnoses, nonclassical radiographic findings, and laboratory delays); the delayed recognition of drug resistance; and the delayed initiation of effective anti-TB treatment. Other factors contributing to nosocomial transmission include delayed initiation of isolation, inadequate ventilation for acid-fast bacillus (AFB) isolation, lapses in maintaining AFB isolation, inadequate duration of AFB isolation, and inadequate precautions during cough-inducing procedures.

Tuberculosis in Other Industrialized Countries

Seven of 15 Western European countries (Denmark, Ireland, Italy, Netherlands, Norway, Spain, and Switzerland) have also recently experienced increases in reported cases (Raviglione et al., 1993). The major factor responsible for most of these increases appears to be immigration from higher-prevalence countries. However, in Italy, 11.4% of AIDS patients reported dur-

ing the biennium 1988 through 1989 had TB (Raviglione et al., 1993).

In Australia, death rates have remained stable at about 0.4/100,000, and notification rates of all cases have slightly increased from 5.6/100,000 in 1986 to 5.9/100,000 in 1990 (Cheah, 1992a). The HIV epidemic has had little impact on the TB situation in Australia. Two-thirds of the new patients reported in 1991 were foreign born (Cheah, 1992b).

In Canada, a similar stagnation of notifications and rates has been observed over the past 6 years. In 1991, 2,044 cases were reported (rate, 7.6/100,000). Foreign-born patients constituted 48% of all patients in 1989, and native Canadians constituted 20% of patients. TB mortality rates were stable at around 0.5/100,000 during recent years (WHO, unpublished data [from the Canadian Centre for Health Information, Ottawa]).

In Japan, the downward trend of TB notifications continues. The average decline between 1980 and 1991 has been 3.5% per year. However, this decline is smaller than that seen in previous years. Furthermore, the incidence of sputum-smear-positive cases has steadily increased since 1980. In general, mortality rates have regularly decreased at about 4.6% per year since 1980 (WHO, unpublished data [from the Japan Anti-Tuberculosis Association, Tokyo]).

In New Zealand, case notifications have recently increased from a nadir in 1988 of 295 cases reported. In 1991, 335 cases were reported (rate, 9.9/100,000). Mortality rates have decreased from 0.9 to 0.5/100,000 during the period 1980 to 1990 (WHO, unpublished data [from the New Zealand Department of Health, Wellington]).

In Israel, TB notifications, after being stable in the 1980s, recently increased to 505 in 1991 (rate, 10.2/100,000). However, if rates for Ethiopian immigrants are excluded from the data, the rate among native Jews in 1991 was 4.6/100,000 and that

among native non-Jews was 3.7/100,000. Ethiopians, who generally constitute less than 25% of all cases, constituted 50% of all cases in 1985 and 55% of all cases in 1991, following two waves of migration (Operation Moses and Operation Shlomo) (WHO, unpublished data [from the Israel Ministry of Health, Jerusalem]).

In Turkey, TB notifications during the past few years have decreased, and in 1990, 24,468 cases were reported (rate, 43.8/100,000) (WHO, unpublished data [from the Turkish Ministry of Health, Ankara]).

DRUG RESISTANCE

Acquired resistance is defined as resistance to at least one anti-TB drug that arises during or after the course of treatment, usually as a result of nonadherence to the recommended regimen or of faulty prescribing. A high level of this type of resistance is a mark of a poorly functioning TB control program.

Primary resistance is defined as the presence of drug resistance to at least one anti-TB drug in a TB patient who has never received prior treatment. It is caused by infection with drug-resistant specimens from another patient excreting a drug-resistant organism; many of these patients acquired resistance as a result of inadequate treatment. Thus, primary resistance is an indicator of efficacy of TB control efforts in the past (Weyer and Kleeberg, 1992).

An accurate picture of the drug resistance problem in the world is not available, because only a limited number of countries (both industrialized and developing) have a reliable drug resistance surveillance system. However, limited available information indicates that, generally speaking, many industrialized countries that faced severe MDR-TB in the late 1950s and early 1960s successfully reduced the problem in a rather short time by improving application of the same regimen used previously and by

successfully introducing rifampin-containing short-course chemotherapy. Thus, the incidence of acquired resistance was substantially reduced, and the incidence of primary resistance remains relatively low. In many developing countries, particularly in Asia, the incidence of acquired resistance remains high and the incidence of primary resistance is higher than that in industrialized countries, because national TB control programs in the developing countries have not been able to achieve a high cure rate over a very long period, even after the introduction of short-course chemotherapy.

This already serious situation may quickly worsen as the HIV epidemic spreads. The HIV epidemic may produce increased levels of both acquired and primary resistance not only by overtaxing the national TB control programs as a result of increased caseload but also by affecting compromised immunity (Kochi et al., 1993).

FUTURE TRENDS

Without recognition of the TB crisis confronting the world and prompt, effective action, the TB epidemic can be expected to worsen for several reasons.

First, demographic forces are at work. Children born in past decades in regions with high population growth rates are now reaching the ages at which morbidity and mortality for TB are high. Even if the age-specific rates of new cases do not increase, the changing sizes of the population age groups will now begin to cause a large increase in the number of TB deaths and new cases.

Second, famine, war, and natural disasters that create large populations of displaced, malnourished people in crowded living conditions may cause increases in TB case rates.

Third, age-specific TB incidence rates can be expected to rise in those areas of the

world where immunity of the population is seriously challenged by HIV infection. By mid-1993, the global cumulative number of persons coinfecting with HIV and tubercle bacilli since the beginning of the HIV pandemic was estimated to be over 5 million (Fig. 1). In addition, HIV seroprevalence among TB patients is expected to increase further in areas like sub-Saharan Africa and to increase at least threefold in areas like Southeast Asia during the next decade. As a result, while about 315,000 persons are estimated to have developed HIV-associated TB in 1990, more than 700,000 people are expected to develop HIV-related TB in 1995. In the year 2000, the figure may reach 1.4 million. In 1990, 4.2% of all TB cases were associated with HIV; in the year 2000, an estimated 13.8% of all TB cases may be associated with HIV (Dolin et al., in press).

In addition, there is the threat of the increasing incidence of drug-resistant strains. This phenomenon is largely a consequence of poorly managed and inappropriately focused TB programs and is accelerated and amplified by the HIV coinfection epidemic. Drug-resistant strains are as contagious as the normal TB bacillus. The cure rates of at least 95% that can be achieved for regular TB fall to 70% or less when isoniazid and rifampin resistance occurs.

If the effectiveness and availability of TB control do not improve substantially over those existing now, more than 30 million TB deaths and 90 million new cases are expected to occur in the last decade of this century. Conservative estimates indicate that the incidence of TB can be expected to increase to 8.8 million cases annually by 1995, 10.2 million cases annually by the year 2000, and 11.9 million cases annually by 2005 (Dolin et al., in press). Demographic factors will account for three-quarters of the predicted increase in new cases. Assuming that the availability and effectiveness of treatment programs remain at the 1990 level, 3 million TB deaths can be

expected to occur annually by 1995, and 3.5 million deaths will be occurring annually by the year 2000. Action must be taken now to avert this global health disaster.

REFERENCES

- Cauthen, G. M., and H. G. Ten Dam. 1988. Annual risk of tuberculosis infection. *Geneva: W.H.O./TB* 88:154.
- Centers for Disease Control and Prevention. 1993. Tuberculosis morbidity—United States, 1992. *Morbidity Mortal. Weekly Rep.* 42:696–704.
- Cheah, D. 1992a. Tuberculosis notification rates, Australia final data for 1986 to 1990. *Communicable Dis. Intell.* 16:234–236.
- Cheah, D. 1992b. Tuberculosis notification rates, Australia, 1991. *Communicable Dis. Intell.* 16:398–400.
- Dolin, P. J., M. C. Raviglione, and A. Kochi. Global tuberculosis incidence and mortality during 1990–2000. *Bull. W.H.O.*, in press.
- Kochi, A. 1991. The global tuberculosis situation and the new control strategy of the World Health Organization. *Tubercle* 72:1–6.
- Kochi, A., B. Varelidz, and K. Styblo. 1993. Multi-drug-resistant tuberculosis and its control. *Res. Microbiol.* 2:104–110.
- Murray, C. J. L., K. Styblo, and A. Rouillon. 1990. Tuberculosis in developing countries: burden, intervention and cost. *Bull. Int. Union Tuberc. Lung Dis.* 65:6–24.
- Narain, J. P., M. C. Raviglione, and A. Kochi. 1992. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. *Tuberc. Lung Dis.* 73:311–321.
- Onorato, I., S. McCombs, M. Morgan, and E. McCray. 1993. HIV infection in patients attending tuberculosis clinics, United States, 1988–1992. *Program Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother.*, abstr. 1363.
- Raviglione, M. C., P. Sudre, H. L. Rieder, S. Spinaci, and A. Kochi. 1993. Secular trends of tuberculosis in Western Europe. *Bull. W.H.O.* 71:297–306.
- Selwyn, P. A., D. Hartel, and I. A. Lewis. 1989. A prospective study of the risk of tuberculosis among intravenous drug abusers with human immunodeficiency virus infection. *N. Engl. J. Med.* 320:545–550.
- Styblo, K., J. Meiger, and I. Sutherland. 1969. The transmission of tubercle bacilli, its trend in a human population. *Bull. Int. Union. Tuberc. Lung Dis.* 42:5–104.
- Styblo, K., and A. Rouillon. 1981. Estimated global incidence of smear-positive pulmonary tuberculosis. Unreliability of officially reported figures on tubercu-

- 95, and 3.5
annually by
en now to
1988. Annual
: W.H.O./TB
- ention. 1993.
s, 1992. Mor-
- on rates, Aus-
unicable Dis.
- on rates, Aus-
. 16:398-400.
Kochi. Global
during 1990-
- situation and
Health Orga-
1993. Multi-
rol. Res. Mi-
- uillon. 1990.
burden, inter-
rc. Lung Dis.
- Kochi. 1992.
loping coun-
prevention.
- d E. McCray.
ng tuberculo-
Program Ab-
rob. Agents
- r, S. Spinaci,
tuberculosis in
-306.
- wis. 1989. A
ulosis among
immunodefi-
ed. 320:545-
- d. 1969. The
d in a human
. Lung Dis.
- imated global
tuberculosis.
s on tubercu-
- losis. *Bull. Int. Union Tuberc. Lung Dis.* 56:118-126.
- Sutherland, I. 1976. Recent studies in the epidemiol-
ogy of tuberculosis, based on the risk of being
infected with tubercle bacilli. *Adv. Tuberc. Res.*
19:1-63.
- Weyer, K., and H. H. Kleeberg. 1992. Primary and
acquired drug resistance in adult black patients with
tuberculosis in South Africa: results of a continuous
national drug surveillance programme involvement.
Tuberc. Lung Dis. 73:106-112.
- World Health Organization. 1989. Childhood tubercu-
losis and BCG vaccine. In *EPI Update Supplement*.
World Health Organization, Geneva.
- World Health Organization. 1993. Global Programme
on AIDS. The HIV/AIDS pandemic: 1993 overview.
WHO/EPA/CNP/EVA/93.1.

Chapter 3

Overview of Clinical Tuberculosis

Philip C. Hopewell

The clinical expression of infection with *Mycobacterium tuberculosis* is quite varied and depends on a number of identified factors. Table 1 lists both host- and microbe-related characteristics as well as the consequences of their interactions that influence the manifestations of tuberculous infection. Among generally healthy persons, infection with *M. tuberculosis* is highly likely to be asymptomatic. Data from a variety of sources suggest that the lifetime risk of developing clinically evident tuberculosis after being infected is approximately 10%, with a 90% likelihood of the infection remaining latent (Comstock, 1982). Only a positive tuberculin skin test indicates the presence of the organism in persons with latent infections. In specific subpopulations, for example, in persons with immunodeficiency states or in infants, the proportions who develop evident tuberculosis are much higher (Allen et al., 1992; Comstock, 1982; Selwyn et al., 1992).

Immunization with bacillus of Calmette and Guérin (BCG) in persons with intact cell-mediated immunity minimizes the risk of early disseminated tuberculosis, especially in children. In addition to host fac-

tors, there probably are factors related to the organism itself, such as its virulence or predilection for specific tissues, that influence the outcome and features of the infection; however, these features of the organism have not been characterized.

The most obvious and important factor influencing the clinical features of tuberculosis is the site of involvement. Prior to the beginning of the epidemic of infection with the HIV, approximately 85% of reported tuberculosis cases were limited to the lungs, with the remaining 15% involving only nonpulmonary sites or both pulmonary and nonpulmonary sites (Farer et al., 1979) (Fig. 1). This proportional distribution is substantially different among persons with HIV infection. Although there are no national data that describe the sites of involvement in HIV-infected persons with tuberculosis, in one large retrospective study of tuberculosis in patients with advanced HIV infection, it was reported that 38% had only pulmonary involvement, 30% had extrapulmonary sites, and 32% had both pulmonary and nonpulmonary involvement (Small et al., 1991). The multiplicity of sites in HIV-infected persons is typical of what is seen in an individual having an immune system that is limited in its ability to contain infection with *M. tuberculosis*. Included in this category are infants, the elderly, and persons with pri-

Philip C. Hopewell • University of California, San Francisco, and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, 1001 Potrero Avenue, Room 5K1, San Francisco, California 94110.

Table 1. Factors influencing the clinical features of tuberculosis

Host factors	Microbial factors	Host-microbe interaction
Age		
Immune status	Virulence of organism (?)	Sites of involvement
Specific immunodeficiency states	Predilection (tropism) for specific tissues (?)	Severity of disease
Malnutrition		
Genetic factors (?)		
Coexisting diseases		
Immunization with bacillus of Calmette and Guérin (BCG)		

mary or secondary immunodeficiency states resulting from coexisting diseases or malnutrition.

SYSTEMIC AND REMOTE EFFECTS OF TUBERCULOSIS

Tuberculosis occurring at any site may produce symptoms and findings that are not specifically related to the organ or tissue involved but, rather, are systemic in nature or are remote from the site of disease. Systemic manifestations of the disease, including fever, malaise, and weight loss, are likely mediated by cytokines, especially tumor necrosis factor alpha (TNF- α). Experimental data suggest that TNF- α is an

important mediator of the systemic effects of the disease (Takashima et al., 1990; Valone et al., 1988). Of the systemic effects, fever is the most easily quantified. The frequency with which fever has been observed in patients with tuberculosis varies from approximately 37 to 80% (Arango et al., 1978; Kiblawi et al., 1981). In a study by Kiblawi and coworkers (Kiblawi et al., 1981) in which the fever response was specifically examined, 21% of patients had no fever at any point in the course of hospitalization for tuberculosis. Of the febrile patients, 34% were afebrile within 1 week and 64% were afebrile within 2 weeks. The median duration of fever after beginning treatment was 10 days, with a range of 1 to




Figure 1. Distribution of sites of involvement in newly reported cases of tuberculosis in 1978 prior to the epidemic of infection with HIV.

109 days. Weight loss, weakness, and malaise appear to be less common but are more difficult to quantify.

In addition to these generalized effects of tuberculosis, there are remote manifestations that are not a result of the anatomic site of involvement. These include hematologic abnormalities, hyponatremia, and psychological disorders. The most common hematologic manifestations of tuberculosis are increases in the peripheral blood leukocyte count and anemia, each of which occurs in approximately 10% of patients with apparently localized tuberculosis (Cameron, 1974; Carr et al., 1964). The increase in leukocyte counts is usually slight, but leukemoid reactions may occur. Leukopenia has also been reported. An increase in the peripheral blood monocyte and eosinophil counts also may occur with tuberculosis. Anemia is common when the infection is disseminated. In some instances, anemia or pancytopenia may result from direct involvement of the bone marrow and thus be a local rather than a remote effect.

Other than weight loss, the most frequent metabolic effect of tuberculosis is hyponatremia, which in one series was found to occur in 11% of patients (Chung and Hubbard, 1969). Hyponatremia is caused by production of an antidiuretic hormone-like substance found within affected lung tissue (Vorken et al., 1970). The poor prognosis that in the prechemotherapy era was associated with hyponatremia was probably related simply to the amount of lung involved and perhaps to adrenal involvement. In addition, because the syndrome of inappropriate secretion of antidiuretic hormone is also associated with central nervous system disorders, hyponatremia may be a feature of central nervous system tuberculosis.

The psychological effects of tuberculosis are very poorly defined but were commonly recognized prior to the advent of effective therapy. These effects include depression and, on occasion, hypomania. The best

descriptions of the psychological alterations in patients with tuberculosis are found in literary works, such as Thomas Mann's *The Magic Mountain*, rather than in medical writings.

In many patients, tuberculosis is associated with other serious disorders, including HIV infection, alcoholism, chronic renal failure, diabetes mellitus, neoplastic diseases, and drug abuse, to name but a few. The signs and symptoms of these diseases and their complications can easily obscure or modify those of tuberculosis and can result in considerable delays in diagnosis or in misdiagnoses for extended periods, especially in patients with HIV infection (Kramer et al., 1990). For this reason it is important that clinicians have an understanding of the diseases with which tuberculosis may coexist and have a high index of suspicion for a combination of the two disorders.

TUBERCULIN SKIN TESTING

As noted above, a positive tuberculin skin test is usually the only evidence of latent tuberculous infection (Sbarbaro, 1986). Among persons with symptoms or clinical findings of tuberculosis, the tuberculin skin test may provide useful diagnostic information. However, in an individual patient a positive test (usually defined as an induration of ≥ 10 mm in immunocompetent persons and ≥ 5 mm in persons with HIV infection) does not establish a diagnosis and a negative test does not exclude tuberculosis. Up to 25% of apparently immunocompetent persons will have negative tuberculin skin tests at the time of diagnosis of tuberculosis (Nash and Douglas, 1980). Among patients with tuberculosis and HIV infection, the frequency of positive tuberculin reactions varies considerably depending on the degree of immune compromise (Reider et al., 1989).




Figure 4. Frontal view, chest radiograph, showing the typical findings of endogenous reactivation tuberculosis in an immunocompetent patient. Note the upper lobe location and cavitation.

endogenous reactivation of latent infection usually causes abnormalities in the upper lobes of one or both lungs. Cavitation (destruction of lung tissue) is common in this form of tuberculosis. The most frequent sites of involvement are the apical and posterior segments of the right upper lobe and the apical-posterior segment of the left upper lobe (Fig. 4). Healing of the tuberculous lesions usually results in development of a scar with loss of lung parenchymal volume and, often, calcification. In the immunocompetent adult with tuberculosis, intrathoracic adenopathy is uncommon but may occur, especially with primary infection. As tuberculosis progresses, infected

material may be spread via the airways into the lower portions of the lung or to the other lung. Erosion of a parenchymal focus of tuberculosis into a blood or lymph vessel may result in dissemination of the organism and a "miliary" (evenly distributed small nodules) pattern on the chest film (Fig. 5).

In patients with HIV infection, the nature of the radiographic findings depends to a certain extent on the degree of immunocompromise produced by the infection. Tuberculosis that occurs relatively early in the course of HIV infection tends to have the typical radiographic findings described above (Chaisson et al., 1987; Pitchenik and




Figure 5. Portion of chest radiograph showing nodular lesions in a patient with disseminated tuberculosis.

Rubinson, 1985). With more advanced HIV disease, the radiographic findings become more "atypical": cavitation is uncommon, and lower lung zone or diffuse infiltrates and intrathoracic adenopathy are frequent (Fig. 6).

Bacteriologic Evaluation

At present, a definitive diagnosis of tuberculosis can be established only by isolation of tubercle bacilli in culture, although tests that identify specific *M. tuberculosis* DNA should soon be available for clinical use. When the lung is involved, sputum is the initial diagnostic specimen of choice. Sputum specimens should be collected at

the time of the initial evaluation. Single early-morning specimens have a higher yield and a lower rate of contamination than pooled specimens. The sensitivity of sputum examination increases with the number of specimens, but there is no increase in cumulative recovery of organisms with more than five specimens, and the increased yield between three and five specimens is slight (Kubica et al., 1975).

There are several ways of obtaining specimens from patients who are not producing sputum. The first and most useful is inducing sputum production by the inhalation of a mist of hypertonic (3 to 5%) saline generated by an ultrasonic nebulizer. This is a benign and well-tolerated procedure, al-

uberculosis in

ways into
or to the
mal focus
ymph ves-
of the or-
distributed
chest film

the nature
ends to a
immuno-
ction. Tu-
rly in the
have the
described
enik and




Figure 6. Frontal view, chest radiograph, showing diffuse infiltration caused by *M. tuberculosis* in a patient with HIV infection.

though bronchospasm may occasionally be precipitated in asthmatics. Samples of gastric contents obtained via a nasogastric tube have lower yields than induced sputum, and the procedure is more complicated and uncomfortable for the patient. However, in children and some adults, gastric contents may be the only specimen that can be obtained.

Usually, fiberoptic bronchoscopy is the next diagnostic step if the sputum is negative or cannot be obtained by induction. In general, the bronchoscopic procedure should include bronchoalveolar lavage and transbronchial lung biopsy. The yield of bronchoscopy has been high both for miliary tuberculosis and for localized disease

(Burk et al., 1978; Danek and Bower, 1979; So et al., 1982). For larger nodular lesions, needle aspiration biopsy may also provide specimens from which *M. tuberculosis* can be isolated. This technique is more suited to the evaluation of lesions when there is a suspicion of malignancy.

In some situations, a therapeutic trial of antituberculosis chemotherapy may be indicated before more invasive studies are undertaken (Gordin et al., 1989). Improvement in the chest film concomitant with antituberculosis treatment would be sufficient reason for making a diagnosis of tuberculosis and continuing with a full course of therapy. If a response is going to occur, it should be seen within 3




Figure 7. Age-specific case rates for the most frequent forms of extrapulmonary tuberculosis.

months of starting treatment. In the United States, the criteria for defining a case of tuberculosis allow for culture negativity if the patient in question has a positive tuberculin skin test and responds to multidrug chemotherapy.

EXTRAPULMONARY TUBERCULOSIS

As noted above, prior to the epidemic of HIV infection, approximately 15% of newly reported cases of tuberculosis involved only extrapulmonary sites (Farer et al., 1979). For reasons that are not understood, as rates of pulmonary tuberculosis decreased, rates of extrapulmonary disease remained constant, resulting in an increasing proportion of cases being extrapulmonary. With the onset of the HIV epidemic, however, both absolute and relative rates of extrapulmonary involvement have increased.

Extrapulmonary tuberculosis presents

more of a diagnostic and therapeutic problem than pulmonary tuberculosis. In part, this problem relates to its being less common and therefore less familiar to most clinicians (Alvarez and McCabe, 1984; Weir and Thornton, 1985). In addition, extrapulmonary tuberculosis involves relatively inaccessible sites, and because of the nature of the sites involved, fewer bacilli can cause much greater damage. The combination of small numbers of bacilli and inaccessible sites makes bacteriologic confirmation of a diagnosis more difficult, and invasive procedures are frequently required to establish a diagnosis.

The relative frequencies of tuberculosis at various sites in persons without immunocompromise are shown in Fig. 1, and distribution by age is shown in Fig. 7 (Farer et al., 1979). As can be seen, in general, the incidence for each extrapulmonary site increases with increasing age, except for lymphatic and meningeal tuberculosis, which

Table 2. Recovery of *M. tuberculosis* from various sites in patients with tuberculosis and HIV infection^a

Specimen	No. positive/no. tested (%)	
	Smear	Culture
Sputum	43/69 (62)	64/69 (93)
Bronchoalveolar lavage	9/44 (20)	39/44 (89)
Transbronchial biopsy	1/10 (10)	7/10 (7)
Lymph node	21/44 (48)	39/44 (91)
Blood		15/46 (33)
Bone marrow	4/22 (18)	13/22 (62)
Cerebrospinal fluid		4/21 (19)
Urine		12/17 (71)
Other ^b	5/31 (16)	24/31 (76)

^a Data are from Small et al. (1991).^b Pleural fluid or tissue, pericardial fluid or tissue, liver peritoneal fluid, abscess drainage, or bone.

are relatively more common in young children.

Extrapulmonary Tuberculosis in HIV-Infected Patients

Presumably, the basis for the frequency of extrapulmonary tuberculosis among patients with HIV infection is the failure of the immune response to contain *M. tuberculosis*, thereby enabling hematogenous dissemination and subsequent involvement of single or multiple nonpulmonary sites. As evidence of this sequence, tuberculosis bacilleemia has been documented in HIV-infected patients on a number of occasions (Handwerger et al., 1987; Kramer et al., 1990; Shafer et al., 1989). Because of the frequency of extrapulmonary tuberculosis among HIV-infected patients, diagnostic specimens from any suspected site of disease should be examined for mycobacteria. Moreover, cultures of blood and bone marrow may reveal *M. tuberculosis* in patients who do not have an obvious localized site of disease but who are being evaluated because of fever. Table 2 lists the sites from which *M. tuberculosis* was recovered in a group of patients with advanced HIV infection (Small et al., 1991).

Disseminated Tuberculosis

The epidemic of HIV infection has considerably altered the frequency and de-

scriptive epidemiology of disseminated tuberculosis. Disseminated or miliary tuberculosis occurs because of the inadequacy of host defenses in containing tuberculous infection. This failure of containment may occur in either latent or recently acquired tuberculous infection. Because of HIV or other causes of immunosuppression, the organism proliferates and disseminates throughout the body. Multiorgan involvement is probably much more common than is recognized, because generally, once *M. tuberculosis* is identified in any specimen, other sites are not evaluated. The term "miliary" is derived from the visual similarity of the lesions to millet seeds. Grossly, these lesions are 1- to 2-mm-diameter yellowish nodules that, histologically, are granulomas. Persons with HIV infection may not be able to form granulomas; thus, the individual lesions may not be present. Instead, a diffuse uniform pattern of lymphocytic infiltration and edema is seen.

Although disseminated tuberculosis nearly always involves the lungs, it is considered among the extrapulmonary forms of the disease because of the multiplicity of organs affected. In the past, miliary tuberculosis occurred mainly in young children; currently, however, except among HIV-infected persons, it is more common among older persons (Farer et al., 1979). The shift

infection^a

Culture
64/69 (93)
39/44 (89)
7/10 (7)
39/44 (91)
15/46 (33)
13/22 (62)
4/21 (19)
12/17 (71)
24/31 (76)

in age-specific incidence presumably has been caused by the paucity of new infections relative to the number of endogenous reactivations that take place in the United States. The sex incidence is nearly equal except in the HIV-infected population, wherein men predominate.

Because of the multisystem involvement in disseminated tuberculosis, the clinical manifestations are protean. The presenting symptoms and signs are generally nonspecific and are dominated by the systemic effects, particularly fever, weight loss, anorexia, and weakness (Grieco and Chmel, 1974; Munt, 1971; Prout and Benatar, 1980; Sahn and Neff, 1974; Slavin et al., 1980). Other symptoms depend on the relative severity of disease in the organs involved. Cough and shortness of breath are common; headache and mental status changes are less frequent and are usually associated with meningeal involvement (Munt, 1971). Physical findings are likewise variable. Fever, wasting, hepatomegaly, pulmonary findings, lymphadenopathy, and splenomegaly occur in descending order of frequency. The only physical finding that is specific for disseminated tuberculosis is the choroidal tubercle, a granuloma located in the choroid of the retina (Massaro et al., 1964).

Initial screening laboratory studies are not particularly helpful for the diagnosis of miliary tuberculosis. Both leukopenia and leukocytosis may be seen, but the majority of patients have normal leukocyte counts. Anemia is common and may be normocytic, normochronic, or microcytic and hypochromic. Coagulation disorders are unusual, but disseminated intravascular coagulation has been reported in association with miliary tuberculosis in severely ill patients (Huseby and Hudson, 1976; Murray et al., 1978). Hyponatremia also occurs, as discussed above. The most frequent abnormality of liver function is an increased alkaline phosphatase concentration. Bilirubin

and alanine aminotransferase levels may also be increased.

The chest film is abnormal in most but not all patients with disseminated tuberculosis. In the series reported by Grieco and Chmel (1974), only 14 (50%) of 28 patients had a miliary pattern on chest film, whereas 90% of 69 patients reported by Munt (1971) had a miliary pattern. Overall, it appears that at the time of diagnosis, approximately 85% of patients have the characteristic radiographic findings of miliary tuberculosis. Other radiographic abnormalities may be present as well. These include upper lobe infiltrates with or without cavitation, pleural effusion, and pericardial effusion. In patients with HIV infection, the radiographic pattern is one of diffuse infiltration rather than discrete nodules.

The tuberculin skin test is positive less frequently in patients with disseminated tuberculosis than in those with other forms of the disease. The rate of positivity at the time of diagnosis in apparently immunocompetent persons ranges from approximately 50 to 75% (Grieco and Chmel, 1974; Munt, 1971; Sahn and Neff, 1974; Slavin et al., 1980). As the disease is treated, tuberculin reactivity tends to return unless there is systemic immunocompromise.

Autopsy series have shown the liver, lungs, bone marrow, kidneys, adrenals, and spleen to be the organs most frequently involved in miliary tuberculosis, but any organ can be the site of disease (Slavin et al., 1980). Because of the multiplicity of sites involved, there are many potential sources of material used to provide a diagnosis. Acid-fast smears of sputum are positive in 20 to 25% of patients, and *M. tuberculosis* is isolated from sputum in 30 to 65% of patients (Grieco and Chmel, 1974; Munt, 1971; Sahn and Neff, 1974; Slavin et al., 1980). Gastric washings or induced sputum may be positive when the patient is not expectorating spontaneously. In a patient with an abnormal chest film and negative sputum examinations, bronchos-

copy should be the next step. Combinations of bronchoalveolar lavage and transbronchial biopsy would be expected to have a high yield. Other potential sites for biopsy include liver and bone marrow, each of which has a high likelihood of showing granulomas (70 to 80%) but only a 25 to 40% chance of providing bacteriologic confirmation (Sahn and Neff, 1974). Urine is easy to obtain and may be positive in up to 25% of patients (Sahn and Neff, 1974). Selection of other potential sources of diagnostic material should be guided by specific findings.

Lymph Node Tuberculosis

Prior to the HIV epidemic, lymph node tuberculosis made up approximately 20% of the cases of extrapulmonary tuberculosis in the United States (Farer et al., 1979). Although the basic descriptive epidemiology of tuberculosis applies to lymphatic tuberculosis, there are two main differences: lymphatic tuberculosis is relatively more common among children, and it occurs more frequently in women. It also appears to be more common among Asians and Pacific Islanders than among blacks and whites. Among HIV-infected persons, the demographic features of tuberculous lymphadenitis parallel those of HIV infection.

Tuberculous lymphadenitis usually presents as painless swelling of one or more lymph nodes. The nodes most commonly involved are those of the posterior or anterior cervical chain or those in the supraclavicular fossa. Frequently, the process is bilateral, and other noncontiguous groups of nodes can be involved (Kent, 1967). At least initially, the nodes are discrete and the overlying skin is normal. With continuing disease, the nodes may become matted and the overlying skin inflamed. Rupture of the node can result in formation of a sinus tract, which may be difficult to heal. Intrathoracic adenopathy may compress bronchi, causing atelectasis and leading to lung infection and perhaps bronchiectasis.

In non-HIV-infected persons with tuberculous lymphadenitis, systemic symptoms are not common unless there is concomitant tuberculosis elsewhere. The frequency of pulmonary involvement in reported series of patients with tuberculous lymphadenitis is quite variable, ranging from approximately 5 to 70%. In HIV-infected persons, lymphadenitis is commonly associated with multiple-organ involvement, although localized lymphadenitis, as described above, may occur as well.

The diagnosis of tuberculous lymphadenopathy is established by lymph node biopsy or aspiration with histologic examination, including stains for acid-fast organisms, and culture of the material. Smears show acid-fast organisms in approximately 25 to 50% of biopsy specimens, and *M. tuberculosis* is isolated in roughly 70% of instances in which the diagnosis is tuberculosis (Huhti et al., 1975). Caseating granulomas are seen in nearly all biopsy samples from immunocompetent patients. In immunodeficiency states, granulomas may be poorly formed or absent (Marchevsky et al., 1985).

Pleural Tuberculosis

The epidemiology of pleural tuberculosis parallels that of the overall pattern for tuberculosis, with the disease being more common among males and increasing in incidence with increasing age between ages 5 and 45 (Farer et al., 1979). As noted above, this epidemiologic pattern is modified by the occurrence of HIV infection, although pleural involvement seems relatively less frequent among HIV-infected persons.

There are two mechanisms by which the pleural space becomes involved in tuberculosis, and the difference in pathogenesis results in different clinical presentations, approaches to diagnosis, treatment, and sequelae. Early in the course of a tuberculous infection, a few organisms may gain

access to the pleural space, and in the presence of cell-mediated immunity, they can cause a hypersensitivity response (Berger and Mejia, 1973; Ellner, 1978). Commonly, this form of tuberculous pleuritis goes unnoticed, and the process resolves spontaneously. In some patients, however, tuberculous involvement of the pleura is manifested as an acute illness with fever and pleuritic pain. If the effusion is large enough, dyspnea may occur, although the effusions generally are small and rarely are bilateral. In approximately 30% of patients, there is no radiographic evidence of involvement of the lung parenchyma; however, parenchymal disease is nearly always present, as evidenced by findings by lung dissections (Stead et al., 1955).

The diagnosis of pleural tuberculosis is generally established by analysis of pleural fluid and/or pleural biopsy. A thoracentesis (aspiration of fluid from the chest) should be performed, and sufficient fluid for cell count, cytologic examination, biochemical analysis, and microbiologic evaluation should be obtained, leaving enough to allow a needle biopsy to be performed if the fluid is exudative and no diagnosis is evident. The fluid is nearly always straw colored, although it may be slightly bloody. Cell counts are usually in the range of 100 to 5,000/ μ l (Jay, 1985). Early in the course of the process, polymorphonuclear leukocytes may predominate, but mononuclear cells soon become the majority. The fluid is exudative, with a protein concentration greater than 50% of the serum protein concentration, and the glucose level may be normal to low.

Because few organisms are present in the pleural space, smears of pleural fluid are rarely positive, and *M. tuberculosis* is isolated by culture in only 20 to 40% of patients with proved tuberculous pleuritis (Levine et al., 1970; Scharer and McClement, 1968). A single blind needle biopsy of the pleura will confirm the diagnosis in approximately 65 to 75% of patients in



whom tuberculous pleuritis is ultimately diagnosed (Levine et al., 1970; Scharer and McClement, 1968). In a patient who has a pleural effusion that remains undiagnosed after a full evaluation, including pleural biopsy, and who has a positive tuberculin skin test reaction, antituberculosis treatment should be initiated.

The second variety of tuberculous involvement of the pleura is a true empyema (pus in the pleura). This condition is much less common than tuberculous pleuritis with effusion and results from a large number of organisms spilling into the pleural space, usually from rupture of a cavity or an adjacent parenchymal focus via a bronchopleural fistula (Johnson et al., 1973). A tuberculous empyema is usually associated with evident pulmonary parenchymal disease on chest films, and air may be seen in the pleural space. In this situation, the fluid is generally thick and cloudy and may contain cholesterol, causing the fluid to look like chyle (pseudochylous effusion). The fluid is exudative and usually has a relatively high leukocyte count, with nearly all of the leukocytes being lymphocytes. Acid-fast smears and mycobacterial cultures are usually positive, making pleural biopsy unnecessary. This type of pleural involvement has a tendency to burrow through soft tissues and may drain spontaneously through the chest wall. An example of this type of tuberculosis is shown in Fig. 8.

Genitourinary Tuberculosis

As with pleural tuberculosis, the epidemiologic pattern of genitourinary tuberculosis parallels that of tuberculosis in general except that the incidence is nearly equal in men and women. The pathogenesis appears to be one of seeding of the kidney at the time of the initial infection and bacilleemia.

In patients with genitourinary tuberculosis, local symptoms predominate, and systemic symptoms are less common (Christensen, 1974; Simon et al., 1977). Dysuria,



ticularly in Africa, coinfection with *M. tuberculosis* and HIV threatens to double or triple the clinical burden of tuberculosis. De Cock notes that "with current resources, existing tuberculosis programs in sub-Saharan Africa will not cope with the increased tuberculosis burden" (De Cock et al., 1992). In the United States, HIV is a major reason for the increase in tuberculosis nationwide since 1985 and is also responsible for structural changes in the epidemiology of the disease that may require a rethinking of control strategies: of prophylaxis and vaccination issues and of the relationship between reactivation and primary disease. Among the urban poor, where HIV and *M. tuberculosis* infections and poor compliance overlap, tuberculosis has become almost a "new disease," as Snider put it, in which the telescoping of the pathological process and the high prevalence of MDR strains combine to produce a dangerous form of active transmission, particularly among late-stage HIV-seropositive patients and AIDS patients (Snider and Roper, 1992). While active transmission has so far been demonstrated mainly in HIV-infected individuals, it should be remembered that *M. tuberculosis* infection in HIV-infected persons is also what shows up first as a result of rapid progression to disease. Thus, although active transmission and transmission of MDR strains are currently thought of as AIDS-associated phenomena, it is possible that both will be eventually be seen in broader populations.

REFERENCES

- Alland, D., G. E. Kalkut, A. Moss, R. A. McAdam, J. A. Hahn, W. Bosworth, E. Drucker, and B. R. Bloom. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. Submitted for publication.
- Allen, S., J. Batungwayo, K. Kerlikowske, A. R. Lifson, W. Wolf, R. Granich, H. Taelman, P. Van De Perre, A. Serufilira, J. Bogaerts, G. Slutkin, and P. Hopewell. 1992. Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. *Am. Rev. Respir. Dis.* 146:1439-1444.
- Andersen, S., and A. Geser. 1960. The distribution of tuberculosis infection among households in African communities. *Bull. W.H.O.* 22:39-60.
- Bermejo, A., H. Veeken, and A. Berra. 1992. Tuberculosis incidence in developing countries with high prevalence of HIV infection. *AIDS* 6:1203-1206.
- Bloom, B. R., and C. J. L. Murray. 1992. Tuberculosis: commentary on a reemergent killer. *Science* 257:1055-1064.
- Braun, M., N. Badi, R. Ryder, E. Baende, Y. Mukadi, M. Nsuami, B. Matela, J. C. Williams, M. Kaboto, and W. Heyward. 1991. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. *Am. Rev. Respir. Dis.* 143:501-504.
- Canetti, G. 1965. *Am. Rev. Respir. Dis.* 92:687.
- Centers for Disease Control. 1991. Nosocomial transmission of multidrug resistant tuberculosis among HIV-infected persons: Florida and New York, 1988-91. *Morbidity and Mortality Weekly Rep.* 40:585-591.
- Daley, C. L., P. M. Small, G. S. Schecter, G. K. Schoolnik, R. A. McAdam, W. R. Jacobs, and P. C. Hopewell. 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. *N. Engl. J. Med.* 326:231-235.
- De Cock, K. M., B. Soro, I. M. Coulibaly, and S. B. Lucas. 1992. Tuberculosis and HIV infection in sub-Saharan Africa. *JAMA* 268:1581-1587.
- Di Perri, G., M. Cruciani, M. C. Danzi, et al. 1989. Nosocomial epidemic of active tuberculosis among HIV-infected patients. *Lancet* ii:1502-1504.
- Elliott, A. M., R. J. Hayes, et al. 1993. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia. *AIDS* 7:981-987.
- Frieden, T. R., T. Sterling, A. Pabloc-Mendez, J. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. *N. Engl. J. Med.* 328:521-526.
- Gaudier, B., and C. Gernez-Rieux. 1962. Étude expérimentale de la vitalité du B.C.G. au cours de la traversée gastro-intestinale chez des enfants non allergiques vaccinés par voie digestive. *Ann. Inst. Pasteur Lille* 13:77-87.
- Grzybowski, S. 1991. Tuberculosis in the third world. *Thorax* 46:689-691.
- Grzybowski, S., G. D. Barnett, and K. Styblo. 1975. Contacts of cases of active pulmonary tuberculosis. *Bull. Int. Union Tuberc.* 50:90-106.
- Hawken, M., P. Nunn, S. Gathua, R. Brindle, P. Godfrey-Faussett, W. Githi, J. Odhiambo, B. Batchelor, C. Gilks, J. Morris, and K. McAdam. 1993. Increased recurrence of tuberculosis in HIV-1-in-

- fectured patients in Kenya. *Lancet* 342:332-337.
- Hopewell, P. C. 1986. Factors influencing the transmission and infectivity of *Mycobacterium tuberculosis*: implications for public health and clinical management, p. 191-216. In M. A. Sande, L. D. Hudson, and R. K. Root (ed.), *Respiratory Infections*. Churchill Livingstone, New York.
- Hopewell, P. C. 1992. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management and control of tuberculosis. *Clin. Infect. Dis.* 18:540-546.
- Markowitz, N., N. I. Hansen, T. C. Wilcosky, P. Hopewell, J. Glassroth, P. A. Kvale, B. T. Mangura, D. Osmond, J. M. Wallace, M. J. Rosen, and L. B. Reichman. 1993. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. *Ann. Intern. Med.* 119:185-193.
- McKeown, T. 1979. *The Role of Medicine: Dream, Mirage or Nemesis?* Basil Blackwell, Oxford.
- Medical Research Council. 1972. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. *Bull. W.H.O.* 46:371-385.
- Moreno, S., J. Baraia-Extaburu, E. Bopuza, F. Parras, M. Perez-Tascon, P. Miralles, T. Vicente, J. C. Alberdi, J. Cosin, and D. Lopez-Gay. 1993. Risk for developing tuberculosis among anergic patients infected with HIV. *Ann. Intern. Med.* 119:194-198.
- Murray, C. J. L., K. Styblo, and A. Rouillon. 1990. Tuberculosis in developing countries: burden, intervention and cost. *Bull. Int. Union Tuberc.* 65:2-19.
- National Tuberculosis Institute. 1974. Tuberculosis in a rural population in South India: a five years epidemiological study. *Bull. W.H.O.* 51:473-488.
- New York City Department of Health. 1993. *Tuberculosis 1992*. New York City Department of Health, New York.
- Pape, J. W., M. E. Stanback, M. Pamphile, M. Boncy, M. M. H. Deschamps, R. I. Verdier, M. E. Beaulieu, W. Blattner, B. Liautaud, and W. D. Johnson, Jr. 1989. Prevalence of HIV infection and high-risk activities in Haiti. *J. Acquired Immune Defic. Syndr.* 3:995-1001.
- Pulmonary AIDS Complications Study. Unpublished data.
- Raj Narain, S., S. Nair, G. Ramanatha Rao, and P. Chandrasekhar. 1966. Distribution of tuberculosis infection and disease among households in a rural community. *Bull. W.H.O.* 34:639-654.
- Rieder, H. L., G. M. Cauthen, G. W. Comstock, and D. E. Snider. 1989. Epidemiology of tuberculosis in the United States. *Epidemiol. Rev.* 11:79-97.
- Riley, R. L., C. L. Mills, W. Nyka, N. Weinstock, P. B. Storey, L. K. Sultan, M. C. Riley, and W. F. Wells. 1959. Aerial dissemination of pulmonary tuberculosis: a two year study of contagion in a tuberculosis ward. *Am. J. Hyg.* 70:185.
- Riley, R. L., and F. O'Grady. 1961. *Airborne Infection: Transmission and Control*. The Macmillan Co., New York.
- Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *N. Engl. J. Med.* 320:545-550.
- Selwyn, P. A., B. M. Sckell, P. Alcades, G. H. Friedland, R. S. Klein, and E. E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. *JAMA* 268:504-509.
- Shafer, R. W., K. D. Chirgwin, A. E. Glatt, M. Dahdouh, S. Landesman, and B. Suster. 1991. HIV prevalence, immunosuppression and drug resistance in patients with tuberculosis in an area endemic for AIDS. *AIDS* 5:399-405.
- Shaw, J. B., and N. Wynn-Williams. 1954. Infectivity of pulmonary tuberculosis in relation to sputum status. *Am. Rev. Tuberc.* 69:724.
- Small, P. M., R. W. Shafer, P. C. Hopewell, S. P. Singh, M. J. Murphy, E. Desmond, M. F. Sierra, and G. K. Schoolnik. 1993. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N. Engl. J. Med.* 328:1137-1144.
- Snider, D. E. 1993a. The impact of tuberculosis on women, children and minorities in the United States. Paper presented at the World Congress on Tuberculosis, Bethesda, Md., 1993.
- Snider, D. E. 1993b. Tuberculosis: the world situation. History of the disease and efforts to combat it. In J. Porter and K. McAdam (ed.), *Tuberculosis: Back to the Future*. John Wiley and Sons, Chichester, United Kingdom.
- Snider, D. E., and W. L. Roper. 1992. The new tuberculosis. *N. Engl. J. Med.* 326:703-705.
- Springett, V. H. 1971. Tuberculosis control in Britain 1945-1970-1985. *Tubercle* 52:136-147.
- Stoneburner, R. L., M. M. Ruiz, J. A. Milberg, S. Schultz, A. Vennema, and D. L. Morse. 1987. Tuberculosis and acquired immunodeficiency syndrome—New York City. *Morbidity and Mortality Weekly Rep.* 36:786-790.
- Stott, H., A. Patel, I. Sutherland, I. Thorup, P. G. Smith, P. W. Kent, and Y. P. Rykushin. 1973. The risk of tuberculosis infection in Uganda, derived from the findings of national tuberculin surveys in 1958 and 1970. *Tubercle* 54:1-22.
- Styblo, K. 1978. Recent advances in tuberculosis epidemiology with regard to the formulation or readjustment of control programmes. *Bull. Int. Union Tuberc.* 53:283-299.
- Styblo, K. 1984. *Epidemiology of Tuberculosis*. VEB

Airborne Infection. The Macmillan

is, E. E. Schoen-
n, A. T. Walker,
pective study of
ntravenous drug
y virus infection.

es, G. H. Fried-
aum. 1992. High
V-infected drug
1 268:504-509.

. E. Glatt, M.
ster. 1991. HIV
drug resistance
ea endemic for

954. Infectivity
ion to sputum

opewell, S. P.
. F. Sierra, and
infection with
uberculosis in
1. *N. Engl. J.*

berculosis on
the United
Congress on

orld situation.
mbat it. *In J.*
osis: Back to
Chichester,

2. The new
-705.
ol in Britain

Milberg, S.
987. Tuber-
yndrome—
ly Rep. 36:

rup, P. G.
1973. The
a, derived
surveys in

ulosis epi-
n or read-
nt. *Union*

sis. VEB

Gustav Fischer Verlag Jena, The Hague, The Neth-
erlands.

Styblo, K. 1989. Overview and epidemiologic assess-
ment of the current global tuberculosis situation
with an emphasis on control in developing coun-
tries. *Rev. Infect. Dis.* 2(Suppl. 2):S339-S346.

Styblo, K., and D. A. Enarson. 1991. Epidemiology of
tuberculosis in HIV prevalent countries, p. 116-136.
In Selected Papers, vol. 24. Royal Netherlands
Tuberculosis Association, The Hague.

Styblo, K., J. Meijer, and I. Sutherland. 1969. The
transmission of tubercle bacilli: its trend in a human
population. Tuberculosis Surveillance Research
Unit report no. 1. *Bull. Int. Union Tuberc.* 42:5-104.

Sunderam, G., R. J. McDonald, T. Maniatis, J. Oleske,

R. Kapila, and L. B. Reichman. 1986. Tuberculosis
as a manifestation of the acquired immunodeficiency
syndrome (AIDS). *JAMA* 256:362-366.

Sutherland, I. 1976. Recent studies in the epidemiol-
ogy of tuberculosis, based on the risk of being
infected with tubercle bacilli. *Adv. Tuberc. Res.*
19:1-63.

Vareldis, B. P., J. Grosset, I. de Kantor, J. Crafton, A.
Laszlo, M. Felton, M. C. Ranglione, and A. Kochi.
1993. *Laboratory Evaluations of Drug Resistant
Tuberculosis*. WHO/TB/93.171. World Health Orga-
nization, Geneva.

Wells, W. F. 1955. *Airborne Contagion and Air Hy-
giene*. Harvard University Press, Cambridge, Mass.

Tuberculosis

PATHOGENESIS, PROTECTION, AND CONTROL

Editor: Barry R. Bloom, Ph.D.

(Howard Hughes Medical Research Institute / Albert Einstein College of Medicine, Bronx, New York)

ASM PRESS • WASHINGTON, DC

hood tuberculosis has become rare. However, the recent increase in the incidence of tuberculosis in New York (New York City Department of Health, 1993) together with the outbreak studies reported by the Centers for Disease Control and Prevention (CDC) (CDC, 1991), suggests that primary tuberculosis as well as tuberculosis due to endogenous reactivation may be on the increase. Several descriptive and analytic studies support this conclusion. First, although tuberculosis as a whole has increased in the United States and elsewhere in the last decade, the age distribution of tuberculosis in both New York and the United States as a whole has shifted, with the major increase coming in blacks and Hispanics in the 25- to 44-year-old age group, that is, in the group at highest risk for HIV infection. In addition, a recent CDC analysis showed that the largest increases in tuberculosis in recent years in the United States have been in states with the highest incidence of AIDS (Snider, 1993a). In another analysis, Bloom and Murray (1992) estimate that about one quarter of the recent rise in tuberculosis incidence in the United States is due to active transmission in hospitals, homeless shelters, prisons, and other communal living situations; about one third was estimated to be due to HIV. Also, a recent study with DNA fingerprinting techniques in New York (Alland et al., submitted) (see chapter 33) suggests that 30 to 40% of tuberculosis is clonal, that is, in grouped strains, which is likely to be the result of active transmission rather than reactivation of old infection (which would be expected to produce many unique strains). Clonality, that is, active transmission, was associated with HIV infection in this study. It seems likely that a significant part of the rise in tuberculosis incidence in recent years, at least in New York and perhaps elsewhere in the United States, is attributable to active transmission, probably in association with HIV infection.

Drug Resistance

A rise in the proportion of all tuberculosis that is MDR has been observed along with the recent upturn in tuberculosis incidence in the United States. This phenomenon is particularly marked in New York. In April 1991, 19% of all prevalent strains in the city were resistant to two or more drugs (Frieden et al., 1993). There are dramatic increases in drug-resistant tuberculosis in surveys in Africa, Asia, and Latin America (Vareldis et al., 1993). Multiple resistance was strongly associated with AIDS and HIV seropositivity. The spread of drug resistance is likely to be related to HIV infection in two separate ways. First, non-compliant populations such as drug users and the homeless have a high risk for HIV infection; thus, individual MDR strains are likely to be generated in these populations as a result of noncompliance with tuberculosis treatment. Second, active transmission is likely among HIV-positive persons and AIDS patients, particularly in congregate settings, as a result of the telescoping phenomenon, i.e., the rapid generation of new infectious cases from new infections among people who may themselves be unusually susceptible. Since these noncompliant populations have a high risk of HIV infection and AIDS, the creation and active transmission of MDR strains are likely to be taking place in the same populations. MDR problems in association with HIV have not been reported from developing countries, but there is clear potential for a similar overlap in countries with intravenous drug use problems and high background rates of tuberculosis, such as Thailand and Brazil.

The "New" Tuberculosis

HIV has profoundly changed the epidemiology of tuberculosis, disrupting the balance between tuberculosis infection and control in both developing and developed countries. In developing countries, and par-

studies	Risk ratio ^b
s	Inf
	Inf
	Inf
	10
	50
	26
	NA
	34

is and BCG
tuberculosis
treatment of

Disease

the natural
Hopewell,
short-term
se that are
rsons who
egative, as
d in Table
robability
osis is 2 to
agnitude
of the rate
is among
/100,000/
red coin-
d, so it is
Table 1
all risk of
well as
tubercu-
over the

classic estimate of an approximately 10% lifetime risk, and a very high proportion of coinfecting persons are at risk of active tuberculosis.

Reported progression rates in the African studies noted in Table 1 appear to be lower than those in the U.S. and Spanish studies, which may reflect an increased probability of primary infection among the intravenous drug users who make up the latter studies. Primary *M. tuberculosis* infection associated with HIV may be relatively rare in African populations, because prevalent *M. tuberculosis* infection rates are very high in adults. Table 1 also suggests, surprisingly, that anergic persons who are HIV positive have the same progression rates to clinical diseases as purified protein derivative-positive patients. Although anergy is common in intravenous drug users for reasons other than HIV, anergic persons will tend to have relatively low CD4 counts and therefore relatively high rates of progression to clinical disease, which may explain this result. It has been recommended that anergic and HIV-positive persons be given chemoprophylaxis against tuberculosis (Selwyn et al., 1992).

Increased Risk of Primary *M. tuberculosis* Infection

Recent outbreaks of multiple-drug-resistant (MDR) tuberculosis in AIDS units and other congregate settings (Centers for Disease Control, 1991) suggest an increased risk of primary infection with *M. tuberculosis*. However, this phenomenon can be distinguished from rapid progression among the infected only when denominator data are available, that is, when it is known how many people were exposed to *M. tuberculosis* infection in the outbreak. It should be remembered that classic studies show infection rates as high as 80 to 100% in some outbreaks in the absence of HIV (Hopewell, 1986). So far, no denominator studies have been published in the HIV era.

Daley et al. (1992), in a study of outbreak in an AIDS patient residence in San Francisco, speculate that at least in late-stage HIV-positive patients, susceptibility to infection was high.

While it is possible that HIV-infected persons are more susceptible to infection with *M. tuberculosis*, there is no evidence that HIV-infected tuberculosis patients are more infectious than tuberculosis cases in general. In a study in Africa, the risk to close contacts of an HIV-positive index case of tuberculosis was not different from the risk to the contacts of an HIV-negative case (Elliott et al., 1993).

Exogenous Reinfection

In the absence of HIV infection, infection with *M. tuberculosis* provides some long-lasting protective immunity against a second infection. However, using RFLP fingerprinting of *M. tuberculosis* isolates (see chapter 33), Small and colleagues have recently demonstrated reinfection by a second *M. tuberculosis* strain in 4 of 19 tuberculosis patients for whom two cultures were available (Small et al., 1993). All were HIV positive. It is likely that in AIDS patients in particular, reinfection with a second strain is a relatively common occurrence. Thus, the view that in developed countries exogenous reinfection plays a very minor role in the etiology of clinical tuberculosis (Styblo, 1984) may not hold for those who are HIV infected.

Primary Transmission

The demonstration of exogenous reinfection raises the issue of the effect of HIV on primary transmission of *M. tuberculosis* in developed countries. Historically, as tuberculosis rates have declined, the burden of tuberculosis in the population has shifted away from primary transmission toward reactivation of old disease. Thus, tuberculosis in developed countries has become increasingly a disease of the old, and child-

Table 1. Risk of clinical tuberculosis in HIV-infected persons in six prospective studies

Study	Subjects ^a	Tuberculosis rate/yr (%)	Risk ratio ^b
Selwyn et al., 1989	HIV ⁺ PPD ⁺ IVDU	7.9	Inf
	HIV ⁻ PPD ⁺ IVDU	0	
	HIV ⁺ PPD ⁻ IVDU	0.3	
Selwyn et al., 1992	HIV ⁻ PPD ⁻ IVDU	0	Inf
	HIV ⁺ anergic IVDU	6.6	
	HIV ⁻ anergic IVDU	0	
	HIV ⁺ PPD ⁺ IVDU (no prophylaxis)	9.7	
Allen et al., 1992	HIV ⁻ PPD ⁺ IVDU (no prophylaxis)	1.0	10
	HIV ⁺ women, Rwanda	2.5	
Braun et al., 1991	HIV ⁻ women, Rwanda	0.05	50
	HIV ⁺ women, Zaire	3.1	
Moreno et al., 1993	HIV ⁻ women, Zaire	0.12	26
	HIV ⁺ PPD ⁺ , Spain	10.4	
	HIV ⁺ anergic, Spain	12.4	
Hawken et al., 1993	HIV ⁺ PPD ⁻ nonanergic, Spain	5.4	NA
	HIV ⁺ Kenyan tuberculosis patients	16.7	
	HIV ⁻ Kenyan tuberculosis patients	0.5	

^a PPD, purified protein derivative; IVDU, intravenous drug user.

^b Inf, infinite risk ratio; NA, not applicable.

Worldwide, tuberculosis as a clinical complication of HIV infection is thought to be due usually to endogenous reactivation of *M. tuberculosis* resulting from the loss of immune control of a latent infection acquired earlier in life. However, recent evidence suggests that the risk of primary transmission of tuberculosis is also increased in both African and U.S. populations (Hawken et al., 1993; Bloom and Murray, 1992).

In HIV-infected groups, the decline in CD4 counts as the infection progresses is associated with increasing anergy (Markowitz et al., 1993), and consequently, skin testing with tuberculin may underestimate the proportion of the population infected with *M. tuberculosis*. In a large study in the United States, about 75% of HIV-infected persons with CD4 counts of less than 200/mm³ were anergic, as were about half of those with CD4 counts between 200 and 400 and about 20% of those with CD4 counts greater than 400. Similar findings were obtained for intravenous drug users and homosexual men (Markowitz et al., 1993). Anergy in the HIV-infected patient compli-

cates decisions about prophylaxis and BCG vaccination, the two principal tuberculosis control measures other than treatment of active cases.

Rapid Progression to Clinical Disease

HIV infection "telescopes" the natural history of tuberculosis infection (Hopewell, 1992). Coinfected persons show short-term progression rates to active disease that are far higher than those among persons who are tuberculin positive but HIV negative, as shown in the studies summarized in Table 1. Among those coinfected, the probability of progression to clinical tuberculosis is 2 to 10%/year, which is 3 orders of magnitude higher than the classic estimates of the rate of developing clinical tuberculosis among the skin test positive (10 to 20/100,000/year). No studies have yet monitored coinfecting individuals for a long period, so it is not clear how long the rates of Table 1 persist. If they do persist, the overall risk of tuberculosis in the coinfecting (as well as the speed of progression to active tuberculosis) is clearly much increased over the

INTERACTION WITH HIV

The epidemic of HIV infection has radically changed the epidemiology of tuberculosis. The overlap of HIV infection and *M. tuberculosis* infection, in developing countries in particular, threatens to produce a public health crisis of the first magnitude. HIV infection is, as Styblo and Enarson (1991) have noted, "the strongest risk factor for tuberculosis disease observed in the last hundred years in subjects infected with tubercle bacilli." To date, the major effect of HIV infection has been to affect the rate of progression to clinical disease in those already infected with *M. tuberculosis*. However, the relationship between the two pathogens is complex, and HIV infection is probably also responsible for increased rates of primary transmission of *M. tuberculosis* in some parts of the world. The overall effect on tuberculosis incidence is enormous, and there is little doubt that HIV will force a reconsideration of tuberculosis control policies in general.

The intimate connection between HIV infection and tuberculosis was demonstrated early in Africa and among intravenous drug users in the United States (De Cock et al., 1992; Stoneburner et al., 1987). It has become clear that, worldwide, tuberculosis is the most common opportunistic infection occurring in patients with AIDS. Of AIDS patients in Latin America, 20 to 30% have tuberculosis, and at least a third of all AIDS patients in African countries present with tuberculosis (De Cock et al., 1992). Among drug users with AIDS in the United States, 21% were reported to develop tuberculosis in one study (Sunderam et al., 1986). However, tuberculosis is rare as an opportunistic infection among HIV-infected homosexual men (Pulmonary AIDS Complications Study, unpublished data). These differences reflect the background prevalence of infection with *M. tuberculosis* in different populations. In African populations and in populations of de-

veloping countries in other parts of the world, about one half are infected with *M. tuberculosis*, reflecting the high annual infection rates that lead to the infection of most of the population by older ages. In the United States, about 7% of homosexual men and 15 to 25% of intravenous drug users are tuberculin positive (Markowitz et al., 1993; Selwyn et al., 1989). Thus, where *M. tuberculosis* infection is prevalent, clinical tuberculosis is common as a complication of AIDS; where it is rare, clinical tuberculosis is also rare in AIDS patients. Tuberculosis as a clinical opportunistic infection appears relatively early in the course of HIV infection, with median CD4 counts at diagnosis of 200 to 300/mm³ in U.S. studies. De Cock suggests that pulmonary tuberculosis occurs at higher CD4 counts and is followed by localized extrapulmonary disease, tuberculosis meningitis, and miliary tuberculosis as the CD4 count falls progressively (De Cock et al., 1992).

In areas where HIV infection is common, a high proportion of cases of tuberculosis are coinfecting with HIV. In some African countries, 15 to 70% of patients presenting with tuberculosis are HIV infected (De Cock et al., 1992; Bermejo et al., 1992), and a rate of 40% has been reported in Haiti (Pape et al., 1989). One quarter of all tuberculosis cases in Haiti were estimated to be attributable to HIV infection, and the rate in Abidjan was 35% (De Cock et al., 1992). Bermejo et al. (1992) estimated that if HIV prevalence reaches 13% of adults in a developing country, tuberculosis rates will double, and Pape et al. (1989) predict that at an HIV prevalence of 10%, tuberculosis rates will triple. Rates of HIV infection in U.S. tuberculosis clinics vary from 5 to 40%, the variation reflecting primarily the proportion of intravenous drug users among AIDS cases. In New York City, about 40% of tuberculosis patients are HIV infected (Shafer et al., 1991; New York City Department of Health, 1993).

of tuberculosis due to reactivation of latent infection. What has yet to be determined is the magnitude of the impact on tuberculosis transmission rates in the community of the large increases in the numbers of cases of tuberculosis among HIV-infected individuals.

the way to select
Socioeconomic development has been consistently associated with declining rates of tuberculosis. However, such changes generally take place over long periods, and in the short term, more rapid interventions are required. The medical intervention that has been most effective in reducing tuberculosis in a community is improved case finding and treatment. Whether the trend in the annual risk of infection is up or down will depend on how many individuals a case of tuberculosis infects on average and how many of these go on to develop clinical disease. If each case on average infects fewer people than would be necessary for one further case to be expected, the incidence of the disease will decline. If the average number of secondary cases is greater than one, the disease incidence will rise. Modern chemotherapy rapidly renders infectious cases sterile for infecting others but obviously has no impact on the number of infections transmitted before the disease was diagnosed, and this number will be critical in determining the trend in the risk of infection in a community. It has been estimated that in developed countries, two or three persons on average may be infected by a smear-positive case before its detection, whereas in developing countries, the number may be four or five because of higher numbers of close contacts (Murray et al., 1990). These numbers vary greatly according to local cultural and treatment conditions. In the absence of treatment, an untreated smear-positive person might infect on average 10 to 14 persons per year (Styblo, 1984). A first priority in control programs must be to ensure the

rapid diagnosis and the effective and complete treatment of patients who report to clinics with symptoms of active tuberculosis (especially smear-positive disease), and once this is achieved, the second priority is to strengthen case detection activities to shorten the average interval between the time a case becomes infectious and the time of diagnosis and treatment (see chapter 33 in this volume).

Contact tracing is used in many control programs to identify those person a case of tuberculosis may have infected or the person from whom the infection was acquired. Generally, this tracing involves examining adults in the same household or the same workplace as a diagnosed patient and examining tuberculin-positive child contacts. While numerous epidemiological studies have demonstrated that close contacts of patients, particularly of those who are sputum positive, are at increased risk of tuberculosis, the majority of tuberculosis patients in the community have probably acquired their disease from an unknown, nonintimate contact (Grzybowski et al., 1975; Raj Narain et al., 1966; Andersen and Geser, 1960). Studies in India (Raj Narain et al., 1966) and Africa (Andersen and Geser, 1960) have illustrated the limited value of tuberculin testing child contacts of patients as a means of case detection because of the relatively high proportions of persons who have been infected with *M. tuberculosis* without evidence of having lived in the same household as an infectious person. For example, in the community study by Raj Narain et al. in India, 41% of children aged less than 15 years in the households of bacillary cases were infected and 19% of children in the households of cases diagnosed by X ray only were infected compared to 12% of children in households without a case of tuberculosis. However, the first two groups accounted for only 15% of all infected children in the community (Raj Narain et al., 1966).

restrict the number of others whom they have the opportunity to infect.

The natural history of tuberculosis following the onset of clinical symptoms is difficult to study because of the availability of very effective treatments, but studies conducted in Britain (Springett, 1971) and in India (National Tuberculosis Institute, 1974) before chemotherapy was widely introduced have produced similar findings. In these studies of sputum-positive patients, about 50% died within 5 years of diagnosis, 30% "self-cured," and the remaining 20% remained alive. In many developing countries, less than half of tuberculosis patients who start treatment are cured or complete their course of chemotherapy (Snider, 1993b), and worldwide, death may still be the most common way in which patients cease to be infectious to others. Poor treatment programs may even worsen the situation by keeping infectious patients alive longer and thus prolonging the period of transmission (Grzybowski, 1991).

TRENDS IN TUBERCULOSIS RATES

Until relatively recently, rates of tuberculosis in developed countries had shown large and consistent declines for many decades. Although it is likely that effective chemotherapy speeded the decline (Styblo, 1989), the major decreases occurred before effective therapy or vaccines were available (McKeown, 1979). Part of the decrease may have been due to the segregation of infectious patients in sanatoria, and the introduction of tuberculin testing of dairy herds and the pasteurization of milk dramatically reduced the incidence of bovine tuberculosis, but the major cause of the decline was related to socioeconomic development. It is not clear exactly what components of socioeconomic development were the determining factors, but as transmission occurs almost exclusively in enclosed environments, improvements in

housing, with better ventilation and reduction of crowding, are likely to have been important changes, as were better levels of nutrition.

The rapidity of the decline in tuberculosis infection rates has been best documented by using the data on annual tuberculin testing of military recruits in The Netherlands. Between 1910 and 1939, the average annual risk of infection in The Netherlands is estimated to have decreased by 5.4% annually, and the rate of decline increased to 12.9% annually between 1940 and 1969 (Styblo et al., 1969), with the change around 1940 coinciding with the introduction of compulsory pasteurization of milk. The later development and use of adequate chemotherapy further accelerated the decrease in the annual risk of tuberculosis infection (Styblo, 1989). In many developed countries, the annual risk of infection is now well below 0.1% per year, although pockets of high transmission remain, mainly among socially deprived groups and in immigrants from developing countries. In 1978, Styblo estimated that the rate of infection in developed countries was halving about every 5 years (Styblo, 1978).

Few recent data on the risks of infection in developing countries are available, but in a large number of tuberculin surveys that were conducted by the World Health Organization in the 1950s through the 1970s in different African countries (the continent with probably the highest rates of infection [Murray et al., 1990]), annual risks of infection varied from about 2 to 5%, and in countries where repeat tuberculin surveys were done at later dates, there was little evidence of declining rates (Stott et al., 1973). Given the economic crises of the last two decades and the deterioration in many tuberculosis control programs, it seems unlikely that infection rates will have declined since then, and indeed, with the onset of the HIV epidemic, increases in the rates of infection seem very likely. What is clear is that HIV infection greatly increases the risk

stances, infections with other mycobacteria in the environment may lead to false-positive skin test responses to the tuberculin test).

At later ages, the immunity of persons who have been previously infected may wane, and they are then at risk of developing active tuberculosis as a consequence of either exogenous reinfection (i.e., acquiring a new infection from another infectious individual) or endogenous reactivation of latent bacilli (i.e., reactivation of a preexisting dormant infection). The relative contributions of these two disease routes, and even the existence of one or the other, have been the subject of considerable controversy over the years. Unfortunately, until very recently, the possibility of distinguishing between the two types of disease in individual patients has not existed, and it has been necessary to employ epidemiological modeling techniques to estimate their respective contributions to the total disease load in a population (Sutherland, 1976). With the development of molecular methods of characterizing strains of tubercle bacilli, using restricted fragment length polymorphisms (RFLPs), the potential exists for determining whether disease in a patient is due to an a "new" infection (one that is currently circulating) or the reactivation of an "old" infection (one that was circulating some time previously) (see chapter 33 in this volume).

Much of the work, i.e., estimating the relative contributions of exogenous reinfection and endogenous reactivation to the total tuberculosis disease load, has been done by using historical data from The Netherlands, where for many years all new recruits to military service were skin tested with tuberculin to assess their previous exposure to *M. tuberculosis*. The proportion found to be tuberculin positive at a specific time measures their cumulative risk of infection up to their current age. By studying such data from successive cohorts of recruits, it is possible to estimate annual

risks of infection and the changes in these risks over time. By also relating changes in infection rates over time to changes in the occurrence of cases of clinical disease, it is possible to estimate the contributions of the different forms of disease at different times (Sutherland, 1976). A broad general conclusion from these studies is that in populations in which infection is common, such as in The Netherlands in the earlier part of the century and in developing countries now, exogenous reinfection is likely to be responsible for a high proportion of new cases of adult disease, whereas when the risk of infection is low, as in developed countries now, the relative contribution of endogenous reactivation is greater, and most disease in adults may have this etiology (Styblo, 1984).

Tuberculosis due to reactivation of latent bacilli is presumed to result from a failure in immune surveillance. For example, immunosuppressive treatment is known to increase the risk of reactivation, and the great increase in the risk of tuberculosis in persons with human immunodeficiency virus (HIV) infection is thought to be attributable mainly, though not exclusively, to reactivation of earlier infections. However, in the great majority of cases, the specific cause of reactivation is unknown and, with the exception of HIV infection, those factors that have been identified can account for only a small proportion of all cases of disease (Rieder et al., 1989).

Disease in adults, whether due to a primary infection, reinfection, or reactivation, is sputum positive in about 50% of cases (Styblo, 1984), and it is these cases that are the main source of infection, or reinfection, in the population (Shaw and Wynn-Williams, 1954). It is for this reason that attempts to reduce the transmission of tubercle bacilli in a population through the treatment of cases focus primarily on the identification and treatment of sputum-positive patients so as to render them sputum negative as rapidly as possible and thus

transmitting tubercle bacilli (Gaudier)

The clearest nuclei were im- as the finding ating system of ulosis patients osure chamber of 156 animals ilosis (Riley et the same exper- air from the nsmission to

tion of bacilli estimated to be d or nodular 10^7 to 10^8 in 5), are major are the dura- dynamics of many health g periods to main unin- ples of sev- cted from a

MODEL OF

in popula- tinct risks: community acilli in a isease fol- n, and the after the activation investiga- ese risks ify them, ht be sus- ific inter-

m tuber-

culosis is suffered by those living in developing countries, but in the recent past, the disease was one of the major causes of morbidity and mortality in the now-developed countries. In the 1940s in those countries, the priority of tuberculosis as a public health problem was perhaps comparable to the priority of cancer today. Consequently, the epidemiology of the disease was subjected to extensive investigation, and most of our present knowledge derives from the studies conducted in developed countries.

To what extent the findings in developed countries are generalizable to those countries where the disease load is now focused remains, in some respects at least, open to question, but a reasonable first approach may be to assume that the general aspects of the epidemiology are similar until proven otherwise. It should be stressed, however, that there is an urgent need for well-conducted epidemiological investigations of the disease in those parts of the world where the disease burden is greatest.

Figure 1 is a diagrammatic representation of the natural history of tuberculosis within individuals as they age and are exposed to infection and reinfection. Disease is generally thought to develop in an individual as a consequence of one of three processes:




Figure 1. Diagrammatic representation of the natural history of tuberculosis within individuals as they age.

progression of primary infection, exogenous reinfection, or endogenous reactivation.

At some time after birth, an individual may be infected with *M. tuberculosis* for the first time. This infection is usually acquired through airborne infection from someone who has active pulmonary tuberculosis, i.e., from whom a smear of sputum suitably stained with an acid-fast dye can be shown to contain tubercle bacilli (so called smear-positive tuberculosis). The age at which this primary infection is acquired depends on how common active tuberculosis is in the community. In many developed countries now, there is a good chance that most individuals will escape infection for their whole lives, whereas in developing countries, many such infections occur in childhood, and a high proportion of individuals are infected by the time they are young adults.

Following primary infection, a small proportion of individuals develop progressive primary disease. This is the kind of disease usually seen in children. In 80% of those who develop this form of the disease, it is manifest within 2 years of infection, and nearly all cases occur within 5 years of infection (Medical Research Council, 1972). Children who develop progressive primary tuberculosis are usually smear negative and are therefore not an important source of infection in the community. Estimates of the magnitude of the risk of progressive primary disease following infection vary considerably, but the risk is of the order of 5 to 10%.

Most people do not develop disease following infection and are assumed to mount an effective immune response to the initial infection that limits proliferation of the bacilli and leads to long-lasting partial immunity both to further infection and to reactivation of latent bacilli remaining from the original infection. Such individuals can be identified by a positive response to a tuberculin skin test (although in some circum-

for long periods and is a significant impediment to the eradication of the disease from a community.

TRANSMISSION OF TUBERCULOSIS

The principal risk for acquiring infection with *Mycobacterium tuberculosis* is breathing (Bloom and Murray, 1992). The concept that microbes may exist in sufficient concentration in the air to cause airborne infection and disease was controversial until the middle of this century. The classic studies of Wells (1955) and his student Riley (Riley and O'Grady, 1961) established beyond doubt that infectious particles containing *M. tuberculosis* were emitted in coughs and sneezes and even in speaking. A sneeze may contain over a million particles with diameters of less than 100 μm , the mean being 10 μm . These particles form droplet nuclei in which evaporation continues until the vapor pressure of the droplet equals the atmospheric pressure. The droplet nucleus is very stable, settles very slowly (about 12 mm/min), and remains suspended in the air for long periods. A 10- μm droplet nucleus may carry perhaps 3 to 10 tubercle bacilli. Dust-associated particles may also carry *M. tuberculosis*. These particles are larger than droplets, but they can be transiently resuspended by air convection and may serve as a reservoir for infectious bacilli.

The infectious capability of droplet nuclei was formally established by Wells (1955) and Riley (Riley et al., 1959), who showed that the number of tubercles in the lungs was equivalent to the number of live bacilli inhaled on droplet nuclei with a settling velocity of about 9 mm/min. Of the inhaled bacilli, only 6% reached the alveoli and produced tubercles; the majority of larger particles settled in the upper respiratory mucosa and were expelled by the ciliated respiratory escalator. Infection can take place by ingestion of tubercle bacilli but is about 10,000-fold less effective than

inhalation of droplets in transmitting tuberculosis, probably because tubercle bacilli are very sensitive to gastric acid (Gaudier and Gernez-Rieux, 1962). The clearest demonstration that droplet nuclei were important for transmission was the finding that when air from the ventilating system of a hospital ward for tuberculosis patients was ducted through an exposure chamber that housed guinea pigs, 71 of 156 animals became infected with tuberculosis (Riley et al., 1959). Interestingly, in the same experiments, UV irradiation of the air from the same ward prevented transmission to guinea pigs.

The number and concentration of bacilli present in the source case, estimated to be between 10^2 and 10^4 in solid or nodular lesions but of the order of 10^7 to 10^8 in cavitory lesions (Canetti, 1965), are major variables in transmission, as are the duration of exposure and the aerodynamics of the exhaled particles. While many health care workers exposed for long periods to patients with tuberculosis remain uninfected, there are dramatic examples of several hundred people being infected from a single index case.

EPIDEMIOLOGICAL MODEL OF TUBERCULOSIS

Disease due to tuberculosis in populations is influenced by three distinct risks: the risk of an individual in the community being infected with tubercle bacilli in a given time period, the risk of disease following shortly after such infection, and the risk of disease occurring long after the original infection owing to the reactivation of latent bacilli. Epidemiological investigations have sought to measure these risks and to identify factors that modify them, particularly those factors that might be susceptible to change through specific intervention measures.

Most of the disease burden from tuber-

Chapter 4

Epidemiology of Tuberculosis

P. G. Smith and A. R. Moss

Clinical medicine is concerned, generally, with how a disease progresses within patients. Clinical research seeks to better understand factors that influence the progression of disease in order to develop therapeutic interventions to prevent or lessen the severity of the pathology associated with the disease. Epidemiological research is complementary to this goal and aims to study the occurrence and determinants of disease in populations. The epidemiologist is as interested in those who do not get the disease as in those who do, since by seeking differences between these two groups, the epidemiologist hopes to identify the determinants of the disease and then with this knowledge seek ways of preventing the disease.

For an understanding of the etiology and transmission dynamics of most infectious diseases, it is important to distinguish between infection and disease. Disease may represent the tip of an iceberg with respect to the overall level of infection in a community. Also, the factors that affect the risk of infection may be quite different from the factors that determine whether an infection

is followed by clinical disease or is asymptomatic. The distinction is of less importance for a disease such as measles, in which disease follows infection in the vast majority of cases and the epidemiology of infection is much the same as that of disease. For other diseases, however, and generally those in which the infectious agent has evolved a better symbiotic relationship with the human host, a relatively small proportion of those who are infected go on to develop clinical disease. Such is the case for tuberculosis.

Study of the epidemiology of tuberculosis has been greatly assisted by the availability of a test for infection, the tuberculin test, that enables us to distinguish those who are infected but without disease from those who are uninfected. The absence of such a test for leprosy, for which it is also assumed that infection with the causative agent is much more common than occurrence of the disease, has greatly impeded the development of knowledge of the natural history and transmission dynamics of that disease.

An indication that the tubercle bacillus has enjoyed a long period of evolution with the human host is the ability of the organism to survive in a latent state and then reactivate many years after the original infection. This ability has enabled the bacillus to survive in small population groups

P. G. Smith • Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. A. R. Moss • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94110.

- tubercles: a clue to hematogenous tuberculosis. *Ann. Intern. Med.* 60:231-241.
- McTammany, J. R., K. M. Moser, and V. N. Houk. 1963. Disseminated bone tuberculosis: review of the literature and presentation of an unusual case. *Am. Rev. Respir. Dis.* 87:888-895.
- Mitchell, R. S., and L. J. Bristol. 1954. Intestinal tuberculosis: an analysis of 346 cases diagnosed by routine intestinal radiography on 5529 admissions for pulmonary tuberculosis, 1924-1949. *Am. J. Med. Sci.* 227:241-249.
- Munt, P. W. 1971. Miliary tuberculosis in the chemotherapy era with a clinical review in 69 American adults. *Medicine* 51:139-155.
- Murray, H. W., C. U. Tuazon, N. Kirmani, and J. H. Sheagren. 1978. The adult respiratory distress syndrome associated with miliary tuberculosis. *Chest* 73:37-43.
- Nash, D.-R., and J. E. Douglas. 1980. Anergy in active pulmonary tuberculosis: a comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. *Chest* 77:32.
- Pitchenik, A. E., and H. A. Rubinson. 1985. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. *Am. Rev. Respir. Dis.* 131:393-396.
- Prout, S., and S. R. Benatar. 1980. Disseminated tuberculosis: a study of 62 cases. *S. Afr. Med. J.* 58:835-842.
- Reider, H. H., G. M. Cauthen, A. B. Bloch, et al. 1989. Tuberculosis and the acquired immunodeficiency syndrome—Florida. *Arch. Intern. Med.* 149:1268.
- Rooney, J. J., J. A. Crocco, and H. A. Lyons. 1970. Tuberculous pericarditis. *Ann. Intern. Med.* 72:73-78.
- Sahn, S. A., and T. A. Neff. 1974. Miliary tuberculosis. *Am. J. Med.* 56:495-505.
- Sbarbaro, J. A. 1986. Skin testing in the diagnosis of tuberculosis. *Semin. Respir. Infect.* 1:234.
- Scharer, L., and J. H. McClement. 1968. Isolation of tubercle bacilli from needle biopsy specimens of parietal pleura. *Am. Rev. Respir. Dis.* 97:466-468.
- Schepers, G. W. H. 1962. Tuberculous pericarditis. *Am. J. Cardiol.* 9:248-276.
- Selwyn, P. A., B. M. Sckell, P. Alcades, G. H. Friedland, R. S. Klein, and E. E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. *JAMA* 268:504-509.
- Shafer, R. W., R. Goldberg, M. Sierra, and A. E. Glatt. 1989. Frequency of *Mycobacterium tuberculosis* bacteremia in patients with tuberculosis in an area endemic for AIDS. *Am. Rev. Respir. Dis.* 140:1611-1613.
- Simon, H. B., A. J. Weinstein, M. S. Pasternak, M. N. Swartz, and L. J. Lunz. 1977. Genitourinary tuberculosis: clinical features in a general hospital. *Am. J. Med.* 63:410-420.
- Singh, M. M., A. M. Bhargava, and K. P. Jain. 1968. Tuberculous peritonitis: an evaluation of pathogenic mechanisms, diagnostic procedures and therapeutic measures. *N. Engl. J. Med.* 281:1091-1094.
- Slavin, R. E., T. J. Walsh, and A. D. Pollack. 1980. Late generalized tuberculosis: a clinical pathologic analysis of 100 cases in the preantibiotic and antibiotic eras. *Medicine* 59:352-366.
- Small, P. M., G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. *N. Engl. J. Med.* 324:289-294.
- So, S. Y., W. K. Lam, and D. Y. C. Yu. 1982. Rapid diagnosis of suspected pulmonary tuberculosis by fiberoptic bronchoscopy. *Tubercle* 63:195-200.
- Stead, W. W., A. Eichenholtz, and H. K. Strauss. 1955. Operative and pathologic findings in 24 patients with the syndrome of idiopathic pleurisy with effusion presumably tuberculous. *Am. Rev. Respir. Dis.* 71:473-502.
- Takashima, T., C. Ueta, I. Tsuyuguchi, and S. Kishimoto. 1990. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. *Infect. Immun.* 58:3286-3292.
- Valone, S. E., E. Rich, R. S. Wallis, and J. J. Ellner. 1988. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole *Mycobacterium tuberculosis*, BCG, and mycobacterial antigens. *Infect. Immun.* 56:3313-3315.
- Vorken, H., S. G. Massy, R. Fallat, L. Kaplan, and C. R. Kleeman. 1970. Antidiuretic principle in tuberculous lung tissue of a patient with pulmonary tuberculosis and hyponatremia. *Ann. Intern. Med.* 72:383-387.
- Weir, M. R., and G. F. Thornton. 1985. Extrapulmonary tuberculosis: experience of a community hospital and review of the literature. *Am. J. Med.* 79:467-478.
- Weiss, W., and H. F. Flippin. 1961. The prognosis of tuberculous meningitis in the isoniazid era. *Am. J. Med.* 242:423-430.

- Kapila. 1986. Central nervous system tuberculosis with the acquired immunodeficiency syndrome and its related complex. *Ann. Intern. Med.* 105:210-213.
- Borhanmanesh, F., K. Hekmat, K. Vaezzadeh, and H. R. Rezai. 1972. Tuberculous peritonitis: prospective study of 32 cases in Iran. *Ann. Intern. Med.* 76:567-572.
- Burack, W. R., and R. M. Hollister. 1960. Tuberculous peritonitis: a study of forty-seven proved cases encountered by a general medical unit in twenty-five years. *Am. J. Med.* 28:510-523.
- Burk, J. R., J. Viroslav, and L. J. Bynum. 1978. Miliary tuberculosis diagnosed by fiberoptic bronchoscopy and transbronchial biopsy. *Tubercle* 59: 107-108.
- Burke, H. E. 1950. The pathogenesis of certain forms of extrapulmonary tuberculosis. *Am. Rev. Tuberc.* 62:48-67.
- Cameron, S. J. 1974. Tuberculosis and the blood. *Tubercle* 55:55-72.
- Carr, W. P., Jr., R. A. Kyle, and E. J. W. Bowie. 1964. Hematologic changes in tuberculosis. *Am. J. Med. Sci.* 248:709-714.
- Chaisson, R. E., G. F. Schecter, C. P. Theuer, G. W. Rutherford, D. F. Echenberg, and P. C. Hopewell. 1987. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy and survival. *Am. Rev. Respir. Dis.* 136:570-574.
- Christensen, W. I. 1974. Genitourinary tuberculosis: review of 102 cases. *Medicine* 53:377-390.
- Chung, D.-K., and W. W. Hubbard. 1969. Hyponatremia in untreated active pulmonary tuberculosis. *Am. Rev. Respir. Dis.* 99:595-597.
- Comstock, G. W. 1982. Epidemiology of tuberculosis. *Am. Rev. Respir. Dis.* 125(Suppl.):8-16.
- Cremin, B. J., R. M. Fisher, and M. W. Levinsohn. 1970. Multiple bone tuberculosis in the young. *Br. J. Radiol.* 43:638-645.
- Damergis, J. A., E. Lefterich, and J. A. Curtin. 1979. Tuberculoma of the brain. *JAMA* 239:413-415.
- Danek, S. J., and J. S. Bower. 1979. Diagnosis of pulmonary tuberculosis by flexible fiberoptic bronchoscopy. *Am. Rev. Respir. Dis.* 119:677-679.
- Ellner, J. J. 1978. Pleural fluid and peripheral blood lymphocyte function in tuberculosis. *Ann. Intern. Med.* 89:932-933.
- Farer, L. S., L. M. Lowell, and M. P. Meador. 1979. Extrapulmonary tuberculosis in the United States. *Am. J. Epidemiol.* 109:205-217.
- Frank, B. R., and E. C. Raffensperger. 1965. Hepatic granulomata: report of a case with jaundice improving on antituberculous chemotherapy and review of the literature. *Arch. Intern. Med.* 115:223-233.
- Gooi, H. C., and J. M. Smith. 1978. Tuberculous pericarditis in Birmingham. *Thorax* 33:94-96.
- Gordin, F. M., G. Slutkin, G. F. Schecter, P. C. Goodman, and P. C. Hopewell. 1989. Presumptive diagnosis and treatment of pulmonary tuberculosis based on radiographic findings. *Am. Rev. Respir. Dis.* 139:1090-1093.
- Grieco, M. H., and H. Chmel. 1974. Acute disseminated tuberculosis as a diagnostic problem: a clinical study based on twenty-eight cases. *Am. Rev. Respir. Dis.* 109:554-560.
- Hageman, J. H., N. D. D'Esopo, and W. W. L. Glenn. 1964. Tuberculosis of the pericardium: a long-term analysis of forty-four proved cases. *N. Engl. J. Med.* 270:327-332.
- Handwerger, S., D. Mildvan, R. Sennie, and F. W. McKinley. 1987. Tuberculosis and the acquired immunodeficiency syndrome at a New York City hospital: 1978-1985. *Chest* 91:176-180.
- Harvey, A. M., and M. R. Whitehill. 1937. Tuberculous pericarditis. *Medicine* 16:45-94.
- Huhti, E., E. Brander, and S. Plohumo. 1975. Tuberculosis of the cervical lymph nodes: a clinical, pathological and bacteriological study. *Tubercle* 56: 27-36.
- Huseby, J. S., and L. D. Hudson. 1976. Miliary tuberculosis and the adult respiratory distress syndrome. *Ann. Intern. Med.* 85:609-611.
- Jay, S. J. 1985. Diagnostic procedures for pleural disease. *Clin. Chest Med.* 6:33-48.
- Johnson, T. M., W. McCann, and W. H. Davey. 1973. Tuberculous bronchopleural fistula. *Am. Rev. Respir. Dis.* 107:30-41.
- Kent, D. C. 1967. Tuberculous lymphadenitis: not a localized disease process. *Am. J. Med. Sci.* 254: 866-874.
- Kiblawi, S. S. O., S. J. Jay, R. B. Stonehill, and J. Norton. 1981. Fever response of patients on therapy for pulmonary tuberculosis. *Am. Rev. Respir. Dis.* 123:20-24.
- Kramer, F., T. Modelewsky, A. R. Walinay, J. M. Leedom, and P. F. Barnes. 1990. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. *Am. J. Med.* 89:451-456.
- Kubica, G. P., W. M. Gross, J. E. Hawkins, H. M. Sommers, A. L. Vestal, and L. G. Wayne. 1975. Laboratory services for mycobacterial diseases. *Am. Rev. Respir. Dis.* 112:773-787.
- Lattimer, J. K. 1965. Renal tuberculosis. *N. Engl. J. Med.* 273:208-211.
- Levine, H., W. Metzger, and D. Lacera. 1970. Diagnosis of tuberculous pleurisy by culture of pleural biopsy specimen. *Arch. Intern. Med.* 126:268-271.
- Marchevsky, A., M. J. Rosen, G. Chrystal, and J. Kleinerman. 1985. Pulmonary complications of the acquired immunodeficiency syndrome: a clinicopathologic study of 70 cases. *Hum. Pathol.* 16:659-670.
- Massaro, D., S. Katz, and M. Sachs. 1964. Choroidal

of chronic constriction (Harvey and Whitehill, 1937). Constriction has also been observed to develop during the course of antituberculous chemotherapy, although this development appears to be uncommon in patients who have had symptoms for less than 3 months. In the series reported by Hageman and coworkers (Hageman et al., 1964), 11 of 13 patients who had symptoms for more than 6 months required pericardiectomy.

The fibrotic reaction noted above progresses to complete fusion of visceral and parietal pericardium and encasement of the heart in a rigid scar. There are various amounts of calcium within the fibrotic mass. Impairment of coronary circulation is common. At this point, the histologic pattern is usually nonspecific; thus, confirmation of a tuberculous etiology is infrequent.

The symptoms, physical findings, and laboratory abnormalities associated with tuberculous pericarditis may be the result of either the infectious process per se or the pericardial inflammation causing pain, effusion, and eventually hemodynamic effects. The systemic symptoms produced by the infection are quite nonspecific. Fever, weight loss, and night sweats are common in reported series (Harvey and Whitehill, 1937; Rooney et al., 1970; Schepers, 1962). Symptoms of cardiopulmonary origin tend to occur later and include cough, dyspnea, orthopnea, ankle swelling, and chest pain. The chest pain may occasionally mimic angina but usually is described as being dull, aching, and often affected by position and by inspiration.

Apart from fever, the most common physical findings are those caused by the pericardial fluid or fibrosis-cardiac tamponade or constriction. Various proportions of patients in reported series have signs of full-blown cardiac constriction when first evaluated. It is assumed that in these patients, the acute phase of the process was unnoticed.

The definitive diagnosis of tuberculous

pericarditis requires identification of tubercle bacilli in pericardial fluid or tissue. Although not conclusive, demonstration of caseating granulomata in the pericardium and consistent clinical circumstances is convincing evidence of a tuberculous etiology. Less conclusive but still persuasive evidence is the finding of another form of tuberculosis in a patient with pericarditis of undetermined etiology. Approximately 25 to 50% of patients with tuberculous pericarditis have evidence of other organ involvement, particularly pleuritis, at the time pericarditis is diagnosed (Gooi and Smith, 1978; Harvey and Whitehill, 1937). Still less direct and more circumstantial evidence of a tuberculous etiology is the combination of a positive intermediate-strength tuberculin skin test reaction and pericarditis of unproven etiology.

REFERENCES

- Allen, S., J. Batungwanayo, K. Kerlikowske, A. R. Lifson, W. Wolf, R. Granich, H. Taelman, P. Van De Perre, A. Serufulira, J. Bogaerts, G. Slutkin, and P. C. Hopewell. 1992. Prevalence of tuberculosis in HIV-infected urban Rwandan women. *Am. Rev. Respir. Dis.* 146:1439-1444.
- Alvarez, S., and W. R. McCabe. 1984. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. *Medicine* 63:25-55.
- Arango, L., A. W. Brewin, and J. F. Murray. 1978. The spectrum of tuberculosis as currently seen in a metropolitan hospital. *Am. Rev. Respir. Dis.* 108: 805-812.
- Auerbach, O. 1951. Tuberculous meningitis: correlation of therapeutic results with the pathogenesis and pathologic changes. II. Pathologic changes in untreated and treated cases. *Am. Rev. Tuberc.* 64:419-429.
- Barrett-Connor, E. 1967. Tuberculous meningitis in adults. *South. Med. J.* 60:1061-1067.
- Berger, H. W., and E. Mejia. 1973. Tuberculous pleurisy. *Chest* 63:88-92.
- Berney, S., M. Goldstein, and F. Bishko. 1972. Clinical and diagnostic features of tuberculous arthritis. *Am. J. Med.* 53:36-42.
- Bhansali, S. K. 1977. Abdominal tuberculosis: experiences with 300 cases. *Am. J. Gastroenterol.* 67:324-337.
- Bishberg, E., G. Sunderam, L. B. Reichman, and R.

of tuberculosis, but actual hepatic tuberculosis of functional consequence is rare. A variety of histologic abnormalities may be seen, but none is specific for tuberculosis unless *M. tuberculosis* is isolated from hepatic tissue (Frank and Raffensperger, 1965). For this reason, all liver biopsy specimens should be cultured for mycobacteria.

Pericardial Tuberculosis

The descriptive epidemiology of pericardial tuberculosis is not well defined, but in general the disease tends to occur among older persons, with approximately 50% of the patients being older than 55 years (Farer et al., 1979). Nonwhites and men have a relatively higher frequency of tuberculous pericarditis. Before the use of anti-tuberculosis chemotherapy, tuberculous pericarditis was found in 0.4 to 1.0% of all autopsied patients and in 3 to 8% of autopsied patients in whom there was other evidence of tuberculosis (Schepers, 1962). A clinical diagnosis of tuberculous pericarditis was made in 0.35% of approximately 10,000 patients with any form of tuberculosis admitted to Kings County Hospital Center, Brooklyn, N.Y., between 1 January 1960 and 31 December 1966 (Rooney et al., 1970).

The pericardium may become involved during the initial bacillema, with early progression to clinically evident disease or recrudescence following a quiescent period. Hematogenous seeding may also occur during the course of endogenous reactivation. Alternatively, there may be direct extension of an adjacent focus of disease into the pericardium. This focus may be in lung parenchyma, pleura, or tracheobronchial lymph nodes. In fact, all of these mechanisms probably occur and may account for some of the variability in the characteristics of the pericardial fluid, severity of the process, and prognosis (Schepers, 1962). It is likely that tuberculin hypersensitivity plays a role in producing

the inflammatory response in the pericardium, as presumably occurs in the pleura. On the other hand, rupture of a caseous lymph node into the pericardium may cause contamination with a much greater number of organisms; a greater inflammatory response with thicker, more purulent fluid; and a greater likelihood of either early or late hemodynamic effects.

The most common form or stage of tuberculous pericarditis is characterized by pericardial effusion with little pericardial thickening or epicardial involvement. The fluid itself is usually serosanguineous or occasionally grossly bloody, is exudative, and has a leukocyte count of 500/mm³ to as high as 50,000/mm³, with an average of 5,000 to 7,000/mm³ (Harvey and Whitehill, 1937). The cells are predominantly mononuclear, although polymorphonuclear leukocytes occasionally predominate. Tubercle bacilli have been identified in pericardial fluid in approximately 25 to 30% of cases (smear and culture combined) (Rooney et al., 1970). Biopsy of the pericardium with both histologic and bacteriologic evaluation is much more likely to provide a diagnosis, although a nonspecific histologic pattern and failure to recover the organisms do not exclude a tuberculous etiology.

With persistence of the inflammation, there is thickening of the pericardium and progressive epicardial involvement. Granulomas, various amounts of free or loculated fluid, and fibrosis may be present during this stage, and evidence of cardiac constriction may begin to appear. The necrosis associated with the granulomatous inflammation may involve the myocardium, with consequent functional and electrocardiographic manifestations.

Although it is not well documented, it appears that if the patient survives the subacute phase without treatment, chronic fibrotic pericarditis nearly always follows. Prior to the advent of antituberculous therapy, 88% of one series of patients who had tuberculous pericarditis developed evidence

slowly growing focal lesion, although a few patients have increased intracranial pressure and no focal findings. The cerebrospinal fluid is usually normal, and the diagnosis is established by computed tomographic or magnetic resonance scanning and subsequent resection, biopsy, or aspiration of any ring-enhancing lesion.

Abdominal Tuberculosis

Tuberculosis can involve any intra-abdominal organ as well as the peritoneum. The age distribution of abdominal tuberculosis shows a relatively higher incidence in young adults and a second peak in older persons. Males and females have a similar incidence. Intra-abdominal tuberculosis has not been common in HIV-infected persons.

Abdominal tuberculosis presumably results from seeding at the time of initial infection and then either direct or late progression to clinical disease. Peritonitis can also be caused by rupture of tuberculous lymph nodes within the abdomen. Intestinal tuberculosis may also result from ingested tubercle bacilli with direct implantation in the gut. Before chemotherapy, tuberculous enteritis was quite common in patients with advanced pulmonary tuberculosis, presumably being caused by bacilli from the lungs that were swallowed. In a prospective study conducted between 1924 and 1949, intestinal abnormalities compatible with tuberculous enteritis were found by contrast radiography in 1, 4.5, and 24.7% of patients with minimal, moderately advanced, and far advanced pulmonary tuberculosis, respectively (Mitchell and Bristol, 1954).

The clinical manifestations of abdominal tuberculosis depend on the areas of involvement. In the gut itself, tuberculosis may occur in any location from the mouth to the anus, although lesions proximal to the terminal ileum are unusual. The most common sites of involvement are the termi-

nal ileum and the cecum, with other portions of the colon and the rectum involved less frequently (Bhansali, 1977). In the terminal ileum or cecum, the most common manifestations are pain, which may be misdiagnosed as appendicitis, and intestinal obstruction. A palpable mass may be noted and, together with the appearance of the abnormality on barium enema or small-bowel films, may easily be mistaken as a carcinoma. Rectal lesions usually present as anal fissures or fistulae or as perirectal abscesses. Because of the concern with carcinoma, the diagnosis often is made at surgery.

For tuberculous peritonitis, pain, often accompanied by abdominal swelling, is commonly the presenting manifestation (Bhansali, 1977; Borhanmanesh et al., 1972; Burack and Hollister, 1960; Singh et al., 1968). Fever, weight loss, and anorexia are also common. Active pulmonary tuberculosis is uncommon in patients with tuberculous peritonitis. Because the process frequently coexists with other disorders, especially hepatic cirrhosis with ascites, the symptoms of tuberculosis may be obscured. The combination of fever and abdominal tenderness in a person with ascites should always prompt an evaluation for intra-abdominal infection, and a paracentesis should be performed. Ascitic fluid in tuberculous peritonitis is exudative (fluid protein content greater than 50% of serum protein concentration) and contains between 50 and 10,000 leukocytes per μl , the majority of them being lymphocytes, although polymorphonuclear leukocytes occasionally predominate (Borhanmanesh et al., 1972; Singh et al., 1968). Acid-fast organisms are rarely seen on smears of the fluid, and cultures are positive in only approximately 50% of patients. Because of the generally low yield from culture of the fluid, laparoscopic biopsy is often necessary to confirm the diagnosis.

Microscopic evidence of liver involvement is common in patients with all forms

sons. Tuberculomas have been reported even in patients who are receiving what should be adequate chemotherapy (Bishberg et al., 1986). The findings produced by tuberculomas may be indistinguishable on computed tomographic scan from those of toxoplasmosis. For this reason, a specific diagnosis should be sought when such lesions are noted.

Meningitis presumably can result from direct meningeal seeding and proliferation during a tuberculous bacilleemia either at the time of initial infection or at the time of breakdown of an old pulmonary focus, or it can result from breakdown of an old parameningeal focus with rupture into the subarachnoid space. The consequences of the subarachnoid space contamination include diffuse meningitis, a localized arteritis, encephalitis, or myelitis. With meningitis, the process takes place primarily at the base of the brain (Auerbach, 1951). Symptoms therefore include those related to cranial nerve involvement in addition to headache, decreased level of consciousness, and neck stiffness. The duration of illness prior to diagnosis is quite variable and relates in part to the presence or absence of other sites of involvement. In most series, over 50% of patients with meningitis have abnormalities on chest film that are consistent with an old or current tuberculous process, often miliary tuberculosis. At autopsy, disseminated disease is found in a very high percentage of patients with meningitis (Auerbach, 1951). In patients with tuberculous meningitis, sputum cultures have been positive in 40 to 50%; thus, a substantial number of patients will have pulmonary and systemic symptoms in addition to those referable to the central nervous system. Arteritis may be the predominant manifestation of meningitis and can result in a variety of focal ischemic syndromes in addition to the symptoms already described.

Physical findings and screening laboratory studies are not particularly helpful in

establishing a diagnosis. In the presence of meningeal signs on physical examination, lumbar puncture is usually the next step in the diagnostic sequence. If there are focal findings on examination or if there are suggestions of increased intracranial pressure, a computerized tomographic scan of the head, if it can be obtained expeditiously, should be performed before the lumbar puncture. With meningitis, the scan may be normal, but it can also show diffuse edema or obstructive hydrocephalus. Tuberculomas are generally seen as ring-enhancing mass lesions.

In tuberculous meningitis, the lumbar puncture usually shows increased opening pressure and the cerebrospinal fluid usually contains between 100 and 1,000 cells per μ l. In approximately 65 to 75% of patients, lymphocytes predominate, whereas polymorphonuclear leukocytes predominate in the remainder of patients, generally early in the course of the illness. The protein concentration is elevated in nearly all patients. Very high (>300 mg/dl) protein concentrations have been associated with a poor prognosis (Weiss and Flippin, 1961). The glucose concentration in cerebrospinal fluid is usually low but not as low as concentrations that occur during pyogenic bacterial meningitis. Acid-fast organisms are seen on smears of cerebrospinal fluid in only 10 to 20% of patients, and the rate of culture positivity varies from 55 to 80% (Barrett-Connor, 1967). A substantial number of patients will have *M. tuberculosis* isolated from other sources, and in the presence of compatible cerebrospinal fluid findings, such isolation is sufficient to diagnose tuberculous meningitis. Given the severity of tuberculous meningitis, a presumptive diagnosis justifies empiric treatment if no other diagnosis can be established promptly.

The other major central nervous system form of tuberculosis, the tuberculoma, presents a more subtle clinical picture than tuberculous meningitis (Damergis et al., 1979). The usual presentation is that of a

narrowing of the joint space. Typically, in the spine these changes involve two adjacent vertebrae and the intervertebral disk. Paravertebral or other para-articular abscesses may develop, with occasional formation of sinus tracts. Although weight-bearing joints are the most common sites for skeletal tuberculosis, any bone or joint may be involved (Berney et al., 1972). In most series, tuberculosis of the spine (Pott's disease) makes up 50 to 70% of the cases reported. In adults, the lower thoracic and upper lumbar vertebrae are most commonly involved, whereas in children, the upper thoracic spine is the most frequent site of vertebral tuberculosis. The hip or knee is involved in 15 to 20% of cases, and shoulders, elbows, ankles, wrists, and other bones or joints are also involved in 15 to 20% of cases. Usually only one bone or joint is involved, but occasionally the process is multifocal (Cremin et al., 1970; McTammany et al., 1963). Evidence of either previous or current pulmonary tuberculosis is found in approximately one-half of the reported patients, and other extrapulmonary sites may also be involved.

The usual presenting symptom of skeletal tuberculosis is pain (Berney et al., 1972). Swelling of the involved joint may be noted, as may limitation of motion and occasionally sinus tracts. Systemic symptoms of infection are not common. Because of the subtle nature of the symptoms, diagnostic evaluations often are not undertaken until the process is advanced. Delay in diagnosis can be especially catastrophic in vertebral tuberculosis, in which compression of the spinal cord may cause severe and irreversible neurologic sequelae, including paraplegia.

The first diagnostic test undertaken is usually a radiograph of the involved area. The typical findings just described represent the more severe end of the spectrum. Early in the process, the only abnormality noted may be soft tissue swelling. Subsequently, subchondral osteoporosis, cystic

changes, and sclerosis may be noted before the joint space is actually narrowed. The early changes of spinal tuberculosis may be particularly difficult to detect by standard films of the spine. Computed tomographic scans and magnetic resonance imaging of the spine are considerably more sensitive than routine films and should be obtained when there is a high index of suspicion of an infectious process.

Confirmation of the diagnosis is obtained by aspiration of joint fluid or periarticular abscesses or by biopsy of bone or synovium with histologic and microbiologic evaluation of the material obtained. Acid-fast stains of joint fluid are positive in 20 to 25% of those examined, and *M. tuberculosis* is isolated in approximately 60 to 80% (Berney et al., 1972). Biopsies of synovium or bone have a higher yield and allow histologic examination as well. Evidence of granulomatous inflammation even in the absence of bacteriologic proof of the diagnosis is sufficient evidence of tuberculosis to begin therapy unless another etiology is found.

Central Nervous System Tuberculosis

Meningitis is the most frequent form of central nervous system tuberculosis; solitary or multiple tuberculomas occur less commonly. The epidemiologic pattern of central nervous system tuberculosis is quite different from either pulmonary or other forms of extrapulmonary tuberculosis in that the peak incidence is in children in the zero- to 4-year age group, but an appreciable number of cases occur in adults (Barrett-Connor, 1967; Farer et al., 1979). Central nervous system disease accounts for only approximately 5% of all cases of extrapulmonary tuberculosis, and the cases are equally divided between males and females.

Central nervous system involvement, especially tuberculomas, seems to occur with greater frequency among HIV-infected per-

hematuria, and frequent urination are common, and flank pain may also be noted. However, the symptoms may be very subtle, and often there is advanced destruction of the kidneys by the time a diagnosis is established (Lattimer, 1965). Genital involvement without renal tuberculosis is more common in women than in men and may cause pelvic pain, menstrual irregularities, and infertility as presenting complaints (Simon et al., 1977). In men, a painless or only slightly painful scrotal mass is probably the most common presenting symptom of genital involvement, but symptoms of prostatitis, orchitis, or epididymitis may also occur (Christensen, 1974). A substantial number of patients with any form of genitourinary tuberculosis are asymptomatic and are detected because of an evaluation for an abnormal routine urinalysis. In more than 90% of patients with renal or genital tuberculosis, urinalyses are abnormal, with the main finding being pyuria and/or hematuria. The finding of pyuria (pus in urine) in an acid urine with no organisms isolated from a routine urine culture should prompt an evaluation for tuberculosis. The suspicion of genitourinary tuberculosis should be heightened by the presence of abnormalities on the chest film. In most series, approximately 40 to 75% of patients have chest radiographic abnormalities, although in many patients, these abnormalities may be the result of previous, not current, tuberculosis (Christensen, 1974; Simon et al., 1977).

When genitourinary tuberculosis is suspected, at least three first-voided early-morning urine specimens should be collected for acid-fast stains and cultures. *M. tuberculosis* is isolated from the urine in 80 to 95% of cases of genitourinary tuberculosis (Christensen, 1974; Simon et al., 1977). Diagnosis of isolated genital lesions usually

requires biopsy, because the differential diagnosis often includes neoplasia as well as other infectious processes.

Significant effects of tuberculosis on renal function are unusual, but renal failure may occur, especially in patients with pre-existing renal disease. Nephrolithiasis and recurrent bacterial infections in seriously damaged kidneys also occur. Hypertension that responds to nephrectomy has also been described but is rare.

Skeletal Tuberculosis

The incidence of tuberculosis involving the joints and bones increases with increasing age and is equally frequent among men and women, overall making up approximately 9% of cases of extrapulmonary tuberculosis (Farer et al., 1979). Compared to blacks and whites, other racial groups are less likely to have skeletal involvement. Skeletal tuberculosis does not appear to be frequent among persons with HIV infection.

It is presumed that most osteoarticular tuberculosis results from endogenous reactivation of foci of infection seeded during the initial bacilleemia, although spread from paravertebral lymph nodes has been postulated to account for the common localization of spinal tuberculosis to the lower thoracic and upper lumbar vertebrae (Burke, 1950). It is also postulated that the predilection for tuberculosis to localize in the metaphyses of long bones is due to the relatively rich blood supply and the scarcity of phagocytic cells in this portion of the bone (Berney et al., 1972). After beginning in the subchondral region on the bone, the infection spreads to involve the cartilage, synovium, and joint space. This produces the typical findings of metaphyseal erosion and cysts and the loss of cartilage, with

Figure 8. Computed tomographic scan of the chest showing a tuberculous empyema with adjacent chest wall involvement (A) and a large chest wall abscess overlying the sternum with mediastinal involvement (B).